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Randomized clinical trials (RCTs) are widely used as the gold standard for comparative medical 
studies.  Using randomization to determine treatment assignment assures that all patients have 
the same chance of being assigned to each treatment group and that the treatment groups are 
comparable in terms of the distributions of prognostic factors.  When treatment groups are not 
comparable, the power of statistical test will be decreased.  Moreover, the problem of imbalance 
becomes more notable when it occurs in the important prognostic factors because it could result 
in a significant bias when assessing differences by treatment group.     
The most intuitive and simple form of randomization is complete randomization.  
However, with complete randomization there is still a chance for an imbalance on prognostic 
factors.  In order to overcome the problem of imbalance when using complete randomization, 
restricted randomization procedures were proposed.  However, some have argued that an 
unintended consequence of the restrictions placed on randomization is that they could create 
patterns that allow for the prediction of future treatment allocation.  Furthermore, some have 
questioned the accuracy of model-based statistical inference using conventional asymptotic test 
under restrictions placed on the treatment allocation. 
This dissertation is concerned with an assessment of the performance of biased-coin 
minimization.  The assessment is twofold.  The first aspect is to determine in terms of balancing 
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properties and also in terms of the probability of predicting treatment assignment when using 
biased-coin minimization.   The second aspect is to compare the results from the classical 
statistical test, log-rank test, based on population model and the randomization test from the 
randomization model while biased-coin minimization is applied.        
 Randomized clinical trials are the gold standard of research for demonstrating the 
efficacy of therapies used to treat patients in the general community.  Allocation methods that 
promote balance in key prognostic factors between treatment groups are important to assure the 
accuracy and validity of results from clinical trials.  It is important to assess the properties of 
dynamic allocation methods to demonstrate the validity of these methods as they are applied in 
research that is designed to develop treatments that are used to enhance the public health.    
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1.0 INTRODUCTION 
1.1 OVERVIEW 
As groups of patients to be compared may differ in some ways even before any treatment is 
applied, one particular concern in interpreting the comparison of different treatments with regard 
to their efficacy is whether the patients allocated to the different treatment groups are comparable 
with respect to important characteristics.1  In addition to the effect of the treatment, other factors 
known as prognostic variables can also influence patient’s response.  Randomized clinical trials 
(RCTs) are widely used as the gold standard for comparative medical studies, whereas 
nonrandomized study designs are commonly criticized as being most susceptible to bias and 
confounding which would cast doubt on the validity of study findings.  The superiority of the 
RTCs is derived from the fundamental use of randomization to determine treatment assignment 
assuring that all patients have the same chance of being assigned to each treatment group and 
that the distribution of prognostic factors would be similar between treatment groups.  However, 
there are some issues with randomization which will be discussed later. 
 An important aspect of the use of randomization for treatment assignment is the reduction 
of selection bias. In most randomized clinical trials, patients sequentially enter the study, and the 
treatment for each patient is assigned at the time of study entry according to an advance 
generated treatment allocation process which should not be predictable. This unpredictability 
eliminates the possibility of identifying future allocations by either observing the allocation 
sequence directly or detecting patterns among the allocations already made.  An investigator’s 
knowledge of the upcoming treatment assignment can introduce bias by his either conscious or 
unconscious selection of patients to receive a preferred treatment.  For example, when the next 
allocation is guessed to be to the ‘experimental’ group (rather than to the ‘control’ group), the 
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investigator may give preferential consideration to a patient with better prognosis for entry into 
the study, thus hoping to ensure a better outcome result for the particular patient as compared to 
a patient who may have comorbid conditions and may have more server toxicity from the 
experimental treatment than with the control treatment. This can easily be accomplished by 
delaying a patient’s entry into the trial until the next allocation of the preferred treatment occurs.  
Frequent occurrence of this tendency could lead to bias treatment assignment and imbalance in 
prognosis profiles between the groups and bias in the treatment comparison.2 
 Other design features, beyond randomization, are also crucial to the validity of RCT 
results such as masking, allocation concealment, and the intent-to-treat approach to data analysis.  
However, this study will focus on discussions of different facets of randomization procedures.  
Randomization procedures can be distinguished into five types: complete randomization, 
restricted randomization, covariate-adaptive randomization, response adaptive randomization, 
and covariate-adjusted response-adaptive randomization.3,4  Complete randomization can 
eliminate selection bias but it may introduce a significant possibility of imbalance in prognostic 
factors between treatment groups.  In order to overcome this disadvantage, restricted 
randomization designs place some constraints on treatment assignments and force clinical trials 
to be balanced.  On the other hand, covariate-adaptive randomization promotes balance by 
treatment on known covariates as well as overall treatment allocation.  Response-adaptive 
randomization can mitigate the ethical issue by skewing the allocation probability to favor the 
treatment that performs better over time.  Finally, covariate-adjusted response-adaptive 
randomization uses both covariate and response information for making treatment assignments.  
A more in-depth overview and discussion for each type of randomization is provided in the next 
section.  
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1.2 RANDOMIZATION METHODS 
1.2.1 Complete Randomization 
Randomization based on a single sequence of random assignments is known as simple 
randomization.5This technique maintains complete randomness of the assignment of a person to 
a particular group.  There are no restrictions placed on the nature of the randomization sequence.  
Assuming the trial has two treatment groups (control versus experimental group), complete 
randomization is equivalent to tossing a fair coin and the side of the coin (i.e., heads =control, 
tails=treatment) determines the assignment of each person.  The distinguish feature of complete 
randomization is that the allocation does not depend on the patient’s prognostic factors or on 
other patient characteristics.2 
Besides simplicity, complete randomization has several attractive properties.  It provides 
optimal protection against certain types of bias.  For example, no selection bias can take place 
because the treatment allocation from complete randomization is not predictable.6  Also, it has 
the advantage of serving as a basis for standard inferential procedures because this method 
ensures that each sequence of allocation is equally likely.7  This eliminates the need for 
probability assumptions on the responses of the individual experimental units and guarantees the 
validity of the stated significance level.8 
Unfortunately, complete randomization suffers from a disadvantage that makes it 
unattractive in practice; the proportion of patients in treatment groups may differ and the 
treatment groups may have different prognostic profiles by chance.2  Ideally, complete 
randomization is expected to have resulted in treatment assignment that would have 
approximately equal number of patients in each treatment group and achieve relative balance of 
all known and unknown prognostic factors between treatment groups.  In practice, it is not 
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unusual to observe disparate sample size or considerable imbalance on important prognostic 
factor between treatment groups, particularly in small trials or trials with many prognostic 
factors.4  It is desirable to ensure an approximately equal number of patients across the treatment 
at several times throughout the trail.  This because there may be time trends, causing a possible 
unintentional bias if a disproportionate number of early patients was assigned to a specific group. 
The main concern with the problem of imbalance is that it will decrease the precision of 
the estimator and the power of statistical test.  It was shown that if a study has power of 0.90 
with an exact equal balance between treatments, power is reduced to less than 0.85 if the 
treatment imbalance (the larger of the two sample fraction) is on the order of 0.70 or greater9yet 
the probability of such extreme imbalance is fairly low.6 
The problem of imbalance becomes more notable when it occurs in an important 
prognostic factor (such as the patient’s condition or the severity of the disease) because it would 
result in bias and confound the treatment comparison.  Improving the balance of patient 
characteristics among the treatment groups potentially increases the accuracy and precision of 
the results, and, thus, it increases the credibility and the acceptance of the results.10,11 
Kernan et al12 investigated the chances of an imbalance for two treatment groups on a 
binary prognostic factor that is present in 15% of patients through a simulation study involving 
10,000 hypothetical trials. The chance that the two treatment groups will differ by more than 
10% for the proportion of patients with the prognostic factor is 33% for a trial of 30 patients, 
24% for a trial of 50 patients, 10% for a trial of 100 patients, 3% for a trial of 200 patients, and 
0.3% for a trial of 400 patients.  They also found that the chance of imbalance is greater when 
the prognostic factor has higher prevalence.  Additionally, Buyse13 stated that the problem of 
imbalance becomes more acute as the sample size decreases and the number of patient 
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characteristics of interest increases.  For a trial of 100 patients, the chance of observing severe 
imbalance (more imbalanced than 40:60) between the two treatment groups is 20% when one 
prognostic factor is considered.  If more prognostic factors are considered, the chance of such an 
imbalance occurring for at least one of factors increases dramatically.  With five characteristics, 
it is up to 68%; with 10 characteristics, it is up to 90%. 
The need for treatment balance across prognostic factors is critically important in 
situations involving small trials, trials with interim analyses that may be stopped early, trials 
where the analysis of subgroups is considered important, or trials where the credibility of an 
unbalanced trial is considered problematic to widespread acceptance of its results.11,14 
Using statistical techniques such as analysis of covariance (ANCOVA) or multiway 
analysis of variance may be considered to adjust for between-group difference with respect to the 
covariates.  However, this approach has several disadvantages.15  Adjustment that is based on 
observed imbalances that had not been specified before the start of the study is undesirable, 
because the statistical analysis of a clinical trial should not be adapted once results are known.  
Second, the results of the adjusted analysis can only be correctly interpreted if the analysis model 
fits the data.  For example, when analysis of covariance is used, the relationship between the 
covariate and the outcome should follow a straight line in each treatment group, and those lines 
have to be parallel.  Often this is unclear, and especially when the study is small and the 
imbalance large, these assumptions may be difficult to verify.  The bias in analysis could be 
exacerbated when the relationship of the covariate to the dependent variable is nonlinear (and 
also raises the likelihood of unequal slops among treatment groups).  Finally, whatever 
adjustment method is used, unbalanced covariates lead to loss of power. The reason is that 
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adding covariates would lower the number of degrees of freedom. This will be irrelevant in large 
trials, but it can have an impact in small trials. 
Therefore, the preferable approach to obtain balance of important prognostic factors 
between groups is to apply treatment allocation methods other than simple randomization.  
 
1.2.2 Restricted Randomization 
1.2.2.1 Permuted block designs 
The permuted block design divides the experiment into blocks of even length and within each 
block randomizes equal number of patients into treatment groups.  The block size is determined 
before beginning the study and should be a multiple of the number of groups (i.e., with 2 
treatment groups, block size of either 4 or 6).  After block size has been determined, all possible 
balanced combinations of assignment within the block (i.e., equal number for all groups within 
the block) must be calculated.  Blocks are then randomly chosen to determine the patients’ 
assignment into the groups. 
Although permuted block will maintain equal or nearly equal group sizes across time, 
selection bias can occur if the investigators are not blinded to block size and treatment 
assignment.  For example, the last treatment of a block can be predicted with certainty if one has 
counted the treatments assigned and has determined the block size.  The decision whether to 
enroll the next study candidate therefore could be inadvertently affected.   
 
1.2.2.2 Efron’s biased coin design 
As a means of limiting selection bias while maintaining treatment groups of approximately equal 
size, "biased coin" design was introduced by Efron.8  This technique introduces an element of 
unpredictability of randomization into an otherwise deterministic scheme.1For a trial with two 
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treatments, the next patient is assigned to either treatment with probability of 0.5 if treatment 
numbers are equal, otherwise patient is assign to the treatment that would reduce the imbalance 
with probability p> 0.5.  As a specific example, Efron proposed taking 𝑝 = 0.67 because he 
showed that when the probability of assignment is 0.67, it would achieve a good compromise 
between treatment imbalance and increased randomness. 
With the probability of assignment equals 0.67, the experiment has an asymptotic 
probability of 0.5 achieving perfect balance for even sample sizes, and an asymptotic 
probability of 0.75 being as close as possible to balanced for odd sample sizes. 
 
1.2.2.3 Wei’s adaptive biased coin design 
In Efron’s biased coin design, the bias of the coin is constant, regardless of the degree of 
imbalance.  Wei proposed an adaptive biased coin design in which the probability of assignment 
adapts according to the degree of imbalance.  The urn design is the most widely studied of the 
adaptive biased coin designs.  Suppose one starts with an urn contains α white and α red balls.  
To determine a treatment assignment a ball is drawn at random and replaced. If the ball is white, 
treatment A is assigned; if the ball is red then treatment B is assigned. Furthermore, β additional 
balls of the opposite color of the ball drawn are added to the urn.  This drawing procedure is 
repeated for each treatment assignment.  In this way, the urn composition is skewed to increase 
the probability of assignment to the treatment that has been selected least often thus far. 
The urn design forces a small trial to be balanced but behaves like complete 
randomization as the size of the trial increases. As a result, the treatment assignments within a 
sequence generated by the urn design are not as predictable as those of other restricted 
randomization procedures, and the vulnerability to bias is reduced.  
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 Even though overall sample size balance by treatment group may be achieved with these 
methods, groups may be generated that are rarely comparable in terms of certain covariates. 
 
1.2.2.4 Stratified randomization 
Stratified randomization is a two-stage procedure in which patients are first grouped into strata 
according to predefined prognostic variables.  Within each stratum, patients are then assigned to 
a treatment group according to separate randomization sequence.16  For example, suppose that 
there is one prognostic factor, age, with two levels: under 65 years and 65 years or older.  A 
separate randomization sequence is employed for each stratum.  There is a possibility to observe 
imbalance within individual strata when stratification randomization is performed because it 
does not force overall balance between treatments.4  For finite samples, with a large number of 
small strata, imbalances are additive across strata, and can result in an overall imbalance of some 
significance.  This is less likely to occur when there are small numbers of large strata. 
 The most commonly used method for implementing a stratified treatment allocation is to 
use permuted blocks that guarantee perfect balance between the treatment groups after entry of a 
certain number of subjects.  This is called stratified blocked randomization.  Consider a trial with 
two treatment groups (control and experimental) and suppose that we wish to take two 
prognostic factors, sex and clinical stage (early versus late) into account when allocating 
treatment.  To balance both, we would form four strata namely: female-early, female-late, male-
early, and male-late. Blocked assignments are generated for each stratum.  A block usually 
comprises four or six randomly ordered treatment assignments and, within each block, equal 
numbers of patients are assigned to each treatment.  Patients are randomized within block after 
block until the study is complete.  Therefore, with permuted block design, there is no imbalance 
within strata or in aggregate as long as all blocks are filled. 
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The balance resulting from stratified blocked randomization can reduce type I error and 
improve power by reducing unwanted variation.  Theoretical benefits include facilitation of 
subgroup analyses and interim analysis.12 However, stratification randomization becomes 
difficult to implement as the number of prognostic factors increases especially if those variables 
have more than 2 levels because the total number of combinations strata soon grows 
exponentially and this can lead to very few sample sizes within strata.  For example, a study with 
4 prognostic variables which have 2, 3, 3 and 4 levels has a total of 2*3*3*4=72 strata.  If only 
100 patients are able to enter the study, some strata will probably contain no patients and many 
more will have only one.  This method therefore may fail to achieve its basic aim for small trials 
or trials with many prognostic variables, since in most strata the first permuted block of 
treatment will be only partially assigned and considerable imbalance between treatment groups 
for any factor or overall could still exist.  Therneau purported that a balance in covariates begins 
to fail when the number of factor level combinations approaches half the sample size.17 Another 
limitation of using a stratified approach is that all continuous valued covariates must be forced 
into strata, often created using arbitrary cutoffs which could ultimately result in large magnitude 
and scale differences across groups thereby creating imbalance and bias. 
  
1.2.3 Covariate-Adaptive Randomization 
To prevent substantial imbalance between treatment groups in trials with a large number of 
prognostic factors, minimization is considered an alternative approach to randomized blocks.  
Minimization was first proposed by Taves18 in 1974 and independently generalized by Pocock 
and Simon19 in 1975.  It is classified as a “dynamic allocation” or “covariate adaptive” method 
10 
 
because the allocation of next patient depends on the current balance of treatments to all previous 
patients with regard to the pre-specified prognostic factors.14,20,21 
Instead of balancing treatment numbers in each possible combination of the prognostic 
variables, minimization aims to balance the marginal treatment totals for each level of each 
factor.  It is done by allocating the new patient to the treatment group in such a way that 
treatment imbalance after allocation of the patient is as small as possible.  Based on the 
characteristics of the new patient, the Taves method adds marginal totals of the corresponding 
covariate categories for each group and compares the totals.18  The patient then is assigned to the 
group with the lower covariate total to minimize imbalance.  In Taves method, the probability of 
allocating the new patient to the preferred treatment group is one: that is, the patient is always 
allocated to the treatment group which results in lower overall imbalance. Such deterministic 
allocation is not desirable from the standpoint of predictability and principle of randomness. 
Pocock and Simon define a more general method where treatment assignment involves 
three parameters: (1) the level of imbalance between treatment groups for any given factor, (2) 
the overall imbalance across all prognostic factors being considered, and (3) the probability with 
which the patient will be allocated to the treatment group which leads to the least overall 
imbalance.19  The level of imbalance between the treatment groups for a particular level of a 
prognostic factor may be calculated in several ways such as standard deviation, variance, range, 
an upper limit of acceptable imbalance or a sign rule.  The most intuitive method is to use the 
standard deviation or variance of the numbers of patients in each treatment group who occupy 
that level of the prognostic factor.  If there are two treatment groups, the standard deviation of 
these numbers is equivalent to the magnitude of the difference between the two numbers.  
Overall imbalance is usually calculated by taking the sum of the individual imbalances and it is 
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calculated for two scenarios if the new patient is allocated to the active treatment or control 
group.  When combining the imbalances across all prognostic factors, it is appropriate to assign 
weights greater than unity to variables that are considered more important to achieve balance on 
because they are more strongly related to outcome than others.  To decrease the predictability of 
treatment assignment, Pocock and Simon provide several formulae which may be used to 
calculate the probability of assigning the patient to the preferred treatment group.19  If there are 
two treatments, the probability of the patient being assigned to the preferred treatment group 
should be chosen in the range from 0.5 to 1.  Pocock has further suggested that a random element 
of between 0.66 and 0.75 should be incorporated into the minimization algorithm in order to 
reduce predictability.  If several treatments are tied with respect to imbalance score, treatment 
assignment is determined at random. 
Minimization has been shown to be superior to stratified randomization in producing 
balance for the separate prognostic factors and overall.19  Although such sequential treatment 
allocation provides good levels of balance at the margins of prognostic factors, there is no 
guarantee that balance will exist within combinations of prognostic factors.22,23  The extent of the 
failure of minimization to balance within strata, however, has neither been explicitly stated nor 
empirically demonstrated.22,23,24  The other concern of this method is that treatment assignment 
sometimes become highly predictable.  This predictability stems from the knowledge of the 
characteristics of earlier patients and the current allocation which may suggest the next 
allocation.  Various modifications have been proposed to overcome the shortcomings of original 
minimization.  For example, to overcome the predictability, Hofmeijeret al.25 developed 
parameterized dynamic minimization (PDM), in which the assigned probability is not fixed but 
depends on the actual level of imbalance of treatment allocations to the patients already enrolled. 
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A contentious aspect of minimization is that, the validity of model-based statistical 
inference using conventional asymptotic tests may be questionable under restrictions placed on 
the treatment allocation,6,9,12 because the distributional properties of treatment effect estimators, 
in situation where minimization has been used, might not be accurately portrayed by 
conventional statistical methods.  Therefore, it is claimed that if minimization is used as the 
method of treatment allocation, the analysis must use permutation tests, rather than the 
asymptotic tests.  However, there is a limited understanding of the impact of using standard 
statistical methods which assume randomness to analyze trials employing minimization 
randomization. 
 
1.2.4 Response Adaptive Randomization 
The response adaptive (RA) randomization is a class of flexible ways of adjusting the future 
treatment assignment probability favoring the treatments observed to have comparatively 
superior responses based on accumulating interim observed information on the previous patients’ 
responses to treatment in the ongoing trial. As the trial progresses, more patients can be assigned 
to the putatively superior treatment based on the accrued data.  The optimization of such a 
scheme can be more efficient in selecting effective treatments or eliminating ineffective ones and 
also more ethical because more patients are treated with effective treatments.  
However, it lacks a mechanism to actively control the imbalance of prognostic factors 
across treatment groups.  The problem of imbalance in prognostic factors can be magnified in 
trials that use RA randomization rather than equal randomization because the former will result 
in smaller sample sizes for inferior treatment groups that may have larger chance of having 
imbalance in prognostic factors across treatment groups.  The other major concern about RA 
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randomization is that it could reduce the statistical power caused by inducing correlation among 
treatment assignments that leads to extra binomial variability.  
 
1.2.5 Covariate-Adjusted Response Adaptive Randomization 
Covariate-adjusted response-adaptive randomization (CARA) procedures extended the RA 
procedures in acknowledging the facts that the patient population is usually heterogeneous and 
that certain patient characteristics may have impact on the outcome of treatment.  Hu and 
Rosenberger3 define a covariate-adjusted response-adaptive (CARA) randomization procedure as 
a design that the treatment allocation probability for a current patient depends on the history of 
previous patients’ treatment assignments, responses and covariates as well as the covariates of 
the current patient. 
 
1.3 STATISTICAL INFERENCE 
There are two principle ways in which the statistical inferential process can be employed.  One 
way is by use of the population model of inference and the other way is by use of the 
randomization model of inference.26   These two methods of statistical inference are described 
below. 
 
1.3.1 The Population Model Based Inference 
The concept of a population model (sometimes known as the classical model) proposed by 
Neyman and Pearson4 is the most commonly used basis for the development of a statistical test. 
The essential feature of the population model is that the experimental groups must be drawn 
randomly from defined relatively large populations.  Another essential feature is that the 
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responses under study are assumed to be distributed within the sampled population in a specific 
mathematically defined distribution.  For example, when the response values result from 
measurements made on an interval scale, the most common assumption is that the population 
values conform to the normal distribution while if the measurements are nominal (categorical), 
the most common assumption is that the population distribution is of a binomial or multinomial 
form. 
Proper tests of the null hypothesis must be consistent with the assumed population 
distribution.  If a normal distribution is postulated, this leads to the classical student’s t statistic 
or Fisher’s F statistic.  The test statistic is referred to the t and F distributions to allow for the fact 
that the samples are small compared to the size of the population.  Therefore, in addition to the 
theoretical premises of population model described above, certain practical assumptions are 
specific to the tests employed under the population model.  For instance, if the t or F test is used, 
it is required that the populations under study be normally distributed and of equal variance.    
One of the benefits of working under the population model is that it is easy to generalize 
the statistical inference, in the sense that it should hold true for all similar experiments in which 
the same populations are randomly sampled.  However, there are two main sources of difficulty 
with the population model of inference.  The first and most important is that it is almost 
impossible to have random samples from defined large populations.  The second is that there is 
always uncertainty how well the assumptions of population model are satisfied. Furthermore, 
when there is evidence to believe that the assumptions about the distribution of the population 
are violated, complicated modifications of the classical tests must be made to control the risks of 
statistical error.  
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1.3.2 The Randomization Model Based Inference 
In contrast to most classical statistical tests which are based on population model, permutation 
tests (or randomization tests) are from the randomization model that does not require any 
statistical assumptions about the data beyond those inherently satisfied due to the randomization 
itself.  The null hypothesis under the randomization model is different from that under a 
population model, which is typically based on the equality of parameters from a known 
distribution.  The essential feature of a permutation test is that, under the null hypothesis of no 
treatment effect, the set of observed responses is assumed to be a set of fixed values that are not 
affected by treatment.9  That is, under the null hypothesis, each patient’s observed response is 
what would have been observed regardless of which treatment group had been assigned.  Then 
the observed difference between the treatment groups depends only on the way in which the 
patients were randomized, i.e., the particular randomization procedure employed.  The measure 
of the treatment group difference is used as the test statistic of permutation tests.  The 
distribution of the permutation test statistic is evaluated over the reference set of all possible 
randomization sequences that could be generated by the method of randomization used.  The 
reference set is then used to evaluate the tail probability value in comparison to the given 
observed test statistic.  The p-value is obtained by evaluating how far in the extremities of the 
permutation distribution the real observed test statistic lies.14  A very small p-value indicates that 
the observed value is quite extreme compared to the reference set providing evidence to conclude 
that there is a difference between treatment groups.  However, the statistical inference under 
randomization model refers only to the actual experiment which has been performed.  
Permutation tests are assumption-free, but depend explicitly on the particular randomization 
procedure used.   
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 One reason why permutation tests are not better known is that there is a steep increase in 
the number of possible permutations of the data as the size and number of randomized groups 
increases.  For instance, when there are two independent groups and the sample sizes are 𝑛1 and 
𝑛2, the number of all possible  ways of assigning the participants to the two groups is 
(𝑛1+𝑛2)!
𝑛1!𝑛2! . 
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2.0 PURPOSE OF THE STUDY 
2.1 STATEMENT OF THE PROBLEMS 
About one quarter of phase III multi-arm cancer clinical trials published in 13 major oncology 
journals from 1995-2005 reported using some form of dynamic allocation (DA) method and the 
frequency of DA use increased over time.27  Yet details sufficient to assess the performance of 
DA are rarely reported.  Further, the distributional properties of treatment effect estimators, in 
situation where dynamical allocation has been used, might not be accurately portrayed by 
conventional statistical methods.  The critical point is that a dynamic allocation assigns treatment 
based on the current participant’s covariates and the covariates and allocations of previous 
participants, and it is unclear what the consequences of this are for the sampling distributions of 
conventional treatment effect estimators.  For simplicity, in this study, we confine our attention 
to the minimization method. 
 
2.2 OBJECTIVES OF THE STUDY 
The first aspect of this study is concerned mainly with the assessment for the performance of 
biased-coin minimization applied to multicenter clinical trials, in terms of balancing properties 
and also in terms of predictability of the next treatment allocation, under various scenarios of 
trials with different sample sizes, different numbers of prognostic factors to be balanced.  These 
assessments are conducted under two situations: (a) clinical site is not included as one of the 
stratification factors, and (b) clinical site is included as one of the stratification factors.  We also 
adopted different treatment imbalance tolerance levels, ranging from 2 to 4 and various 
assignment probabilities of the biased-coin, ranging from 0.6 to 0.8 to investigate how these two 
parameters in the biased-coin minimization algorithm affect its performs. 
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Using conventional methods like the log-rank test for conducting hypothesis tests for 
trials that employed biased-coin minimization may be inconsistent with statistical theory; many 
statisticians feel that in practice, there will not be substantial differences between the log-ranked 
test and the randomization test.  Thus, another aspect of this study is to compare the results from 
the log-ranked test and randomization test to evaluate such claims under a variety of trial 
scenarios and also distinguish the situations in which the permutation test might be necessary 
from those in which it might not.  
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3.0 METHODS 
3.1 DESCRIPTION OF STUDY POPULATIONS 
Data from three of randomized clinical trial populations from the National Surgical Breast and 
Bowel Project (NSABP) will be used in undertaking work on this dissertation.  These trials 
include B-24, B-28 and P-1.  Some background information for these three studies is provided 
below.  The number of patients and center involved, and the number of prognostic factors 
included in the minimization algorithms in these three trials are detailed in Table 3.1.  Also, 
Tables A1, A2 and A3 of the Appendix A provide the distributions of some key demographic 
and tumor characteristics by treatment groups for these three trials. 
 
Table 3.1 The number of patients and clinical sites involved, and the number of prognostic 
factors in three NSABP trials 
Trial 
Number of 
Patients 
Number of 
Clinical Sites 
Number of Patients 
Per Site (range, mean, 
median) 
Number of 
Stratification Factors 
other than Clinical Site 
B-24 1,801 260 (1-18, 6.9, 3) 1 
B-28 3,060 208 (1-97, 15.0, 9) 3 
P-1 13,388 129 (3-409, 103.8, 87) 4 
 
3.1.1 NSABP B-24 Trial 
The specific aim for the B-24 trial28 was to determine, for patients with noninvasive intraductal 
cancer (DCIS), whether lumpectomy and breast irradiation plus prolonged tamoxifen therapy is 
more effective than lumpectomy and breast irradiation without tamoxifen in preventing the 
subsequent development of ipsilateral and contralateral breast cancers. Women with DCIS were 
eligible for inclusion in the study if their life expectancy was at least 10 years. A total of 1,804 
patients were randomly assigned radiation therapy to the ipsilateral breast and placebo or 
radiation therapy followed by tamoxifen.  To avoid an imbalance in characteristics according to 
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treatment assignment, biased-coin minimization with respect to age (≤49 years or >49 years) was 
performed. 
 
3.1.2 NSABP B-28 Trial 
The B-28 trial29 was designed to determine whether four cycles of adjuvant paclitaxel (Taxol®) 
after four cycles of adjuvant doxorubicin/cyclophosphamide (AC) will prolong disease-free 
survival (DFS) and overall survival (OS) compared with four cycles of AC alone in patients with 
resected operable breast cancer and histologically positive axillary lymph nodes.  Eligible 
patients must have had no evidence of metastatic disease and should have undergone either 
lumpectomy plus axillary node dissection or total mastectomy plus axillary node dissection.  
Patients assignment to the two treatment groups was balanced with respect to histologic nodal 
status (1-3, 4-9, ≥10 positive nodes), assigned tamoxifen administration (no, yes), type of surgery 
(mastectomy, lumpectomy) and institution using biased-coin minimization.  A total of 3,060 
patients were randomized to this trial. 
 
3.1.3 NSABP P-1 Trial 
The primary aim of the P-1 trial30 was to test the hypothesis that long-term treatment with 
tamoxifen is effective in preventing invasive breast cancer among women who never had breast 
cancer but were at high risk for developing this disease. Women at increased risk for breast 
cancer because they: 1) were 60 years of age or older, 2) were 35–59 years of age with a 5-year 
predicted risk for breast cancer of at least 1.66%; or 3) had a history of lobular carcinoma in situ 
were randomly assigned to receive placebo or 20 mg/day tamoxifen for 5 years.  Patients 
assignment to the two treatment groups was balanced using biased-coin minimization with 
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respect to age (35–49 years, 50–59 years, ≥60 years), race (black, white, other), history of LCIS 
(yes, no), and breast cancer RR (<2.5, 2.5–3.9, ≥4.0).  There were 13,388 women randomized to 
this study. 
 
3.2 MINIMIZATION ALGORITHM USED IN NSABP 
The minimization algorithm used in NSABP trials is biased-coin minimization which 
incorporates a random element 𝑝𝑎𝑠𝑠𝑖𝑔𝑛 (e.g. 𝑝𝑎𝑠𝑠𝑖𝑔𝑛 = 0.6), balancing on clinical site and 
selected prognostic factors.  The process of the minimization is shown in Figure 1.  Suppose that 
a new patient enters the study with two treatment groups (A and B), and that his (or her) levels of 
the m prognostic variables are 𝑟1, 𝑟2, etc., up to 𝑟𝑚.  In order to make the allocation for the new 
patient, we first find the numbers of patients being allocated to A and B so far for the same levels 
𝑟1, 𝑟2, … , 𝑟𝑚 of the variables as the new patient about to be randomized.  Suppose that the 
numbers of patients at Level 𝑟1 of variable 1 already allocated to A and to B are 𝑎1 and  𝑏1 
respectively.  For Level 𝑟2 of variable 2, suppose that the corresponding numbers are 𝑎2 and 𝑏2, 
and so on up to Level 𝑟𝑚 of variable m, where the numbers already allocated to A and B are 𝑎𝑚 
and 𝑏𝑚 respectively.  Then, For each treatment group, sum the numbers of patients across all 
stratification factors to obtain the total for treatment A and treatment B.   The difference between 
the sum for treatment A and that for treatment B is used as the imbalance metric to determine the 
preferred treatment group during minimization.  When the imbalance score exceed a pre-
specified tolerance value then the difference in stratification factors between treatment groups is 
viewed as imbalanced otherwise it is regarded as balanced.  Tolerance values of 2 to 4 are used 
for the work.  When the treatment groups are imbalanced, the treatment group that will most 
reduce imbalance get 60% probability of assignment while when the treatment groups are 
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balanced, the assign probability to each treatment groups is equal (i.e. 𝑝𝑎𝑠𝑠𝑖𝑔𝑛 = 0.5).  Various 
assignment probabilities ranging from 0.6 to 0.8 are performed for the work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imbalanced (imbalance score >4) 
The treatment group that will most reduce 
imbalance get 60% probability of assignment 
Find the numbers of patients being allocated to treatment A and 
treatment B so far, for the same levels of each stratification factors as 
the new patient about to be randomized  
For each treatment group, sum the numbers of patients across all 
stratification factors to obtain the total for treatment A and treatment 
B..  The difference between the totals for treatment A and treatment 
B is used as treatment imbalance score to determine the preferred 
treatment group during minimization 
 
Balanced (imbalance score ≤4) 
The assign probability to each treatment 
group is equal (i.e. 𝑝𝑎𝑠𝑠𝑖𝑔𝑛 = 0.5) 
Figure 1. The biased-coin minimization algorithm used in NSABP trials 
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3.3 ASSESSMENT OF THE PERFORMANCE OF THE BIASED-COIN 
MINIMIZATION ALGORITHM 
The clinical site and stratification data of the actual populations in the three NSABP trials 
described above were used to generate the randomizations.  Each population was randomized 
1,000 times under each imbalance tolerance level and biased-coin probability. 
 
3.3.1 Balancing Properties of Biased-Coin Minimization  
Data from each set of 1,000 randomizations was used to determine the balancing performance of 
biased-coin minimization.  Specifically, we will assess: 1) the overall treatment imbalance; 2) the 
treatment imbalance within the levels of stratification factors; and 3) the treatment imbalance 
within clinical centers with more than 15 patients randomized.  The overall treatment imbalance 
𝑡𝐴𝐵, defined as the absolute difference in the total number of treatment A and treatment B 
assignment made in the trial.  The treatment imbalance within the levels of stratification factors 
was determined as the maximum imbalance within the levels is greater than 4.  Assuming we 
take into account P stratification factors with 𝑙1, 𝑙2, … , 𝑙𝑝 levels, the treatment imbalance for 
factor i is defined as  
𝑡𝐴𝐵(𝑓𝑎𝑐𝑡𝑜𝑟 𝑖) = 𝑚𝑎𝑥
⎩
⎨
⎧
𝑡𝐴𝐵(𝑖,1)(𝑓𝑎𝑐𝑡𝑜𝑟 𝑖, 𝑙𝑒𝑣𝑒𝑙 1),
𝑡𝐴𝐵(𝑖,2)(𝑓𝑎𝑐𝑡𝑜𝑟 𝑖, 𝑙𝑒𝑣𝑒𝑙 2),… … … … … … … … … … … … ,
𝑡𝐴𝐵(𝑖,𝑙𝑖)(𝑓𝑎𝑐𝑡𝑜𝑟 𝑖, 𝑙𝑒𝑣𝑒𝑙 𝑙𝑖)⎭⎬
⎫
 .   
The 𝑡𝐴𝐵(𝑖,𝑗) (𝑓𝑎𝑐𝑡𝑜𝑟 𝑖, 𝑙𝑒𝑣𝑒𝑙 𝑗) = �𝑁𝐴,𝑛(𝑖,𝑗) − 𝑁𝐵,𝑛(𝑖,𝑗)� where 𝑛(𝑖, 𝑗) is the number of patients 
with level j for factor i and d is the pre-specified imbalance tolerance, which will be 4 in this 
study.   The treatment imbalance within clinical sites with more than 15 patients randomized was 
determined as the proportion of clinical sites with more than 15 for whom the absolute difference 
between the number of treatment A and treatment B at that center is greater than 4. 
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The treatment allocation was simulated 1,000 times and thus these balancing 
measurements given above were evaluated over the set of 1,000 replications.  As a result we 
obtained distribution functions of the three balancing properties defined above. 
 
3.3.2 Predictability of Next Treatment Allocation 
We adopted three different methods whereby one might predict the next treatment allocation 
identified by Hills et al.28 to mimic how one may attempt to predict the next treatment allocation.  
The different methods of prediction are described below. 
Method 1: Prediction based upon knowledge of the previous treatment allocation only, whereby 
the alternative treatment to that previously allocated to the site is predicted. 
Method 2: Prediction based upon knowledge of all previous allocations to the clinical site and 
the treatment group with the least number of patients is predicted. 
Method 3: Prediction as in method 2, however based upon only the previous three allocations to 
the clinical site. 
Predictability was measured as the percentage of treatment allocations that are predicted 
correctly, that is those corresponding to the treatment allocation identified via the minimization 
method employed.  The prediction of the first treatment allocation is considered as “pure 
guesswork” as there is no information upon which to base a guess.  In addition, for methods 2 
and 3, occasionally the number of patients in each treatment group at the time of prediction is 
equal (for method 3 this occurs when only two patients have been randomized), and hence the 
prediction of treatment allocation cannot be based on the knowledge of previous allocations.  
The predictions in this situation are also classed as “pure guesswork.”  The calculation of 
predictability did not include these “pure guesswork” situations. 
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Prediction rates were calculated for each clinical site and used to calculate mean 
prediction rates per trial.  We then calculated the average predictability rates over the 1,000 
simulated treatment allocation sequences. 
 
3.4 COMPARISON OF RESULTS FROM THE LOG-RANK TEST AND THE 
RANDOMIZATION TEST 
3.4.1 Simulation Framework for Assessing the Agreement between the Log-rank Test and 
the Randomization Test 
We generated parameters with similar distributions as those in the populations of the three 
NSABP trials mentioned in the previous section in terms of sample size, censoring distribution 
and baseline hazard function in each trial.   
The steps used to generate a right-censored data set are shown below. 
STEP 1: Generate stratification variables  
- Generate stratification variables from a binomial distribution (for 2-level variable) or 
multinomial distribution (for multilevel variable) with the frequency distributions of 
variables from the actual population in each trial.   
STEP 2: Generate the sequence of randomization 
- Generate the time, trand, at which the patient was randomized to the treatment group 
following an uniform distribution within the accrual time of the trial.    
STEP 3: Generate treatment variable 
- Treatment assignment is determined by applying biased-coin minimization algorithm 
incorporating with imbalance tolerance level=2 and the biased-coin probability=0.7 to 
have balanced treatment assignment.  
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STEP 4: Generate the randomly right censored observations 
- Generate time from trial start to theoretical event, 𝑡𝑡ℎ𝑒𝑜𝑟𝑦, from an exponential 
distribution (i.e. assuming the baseline hazard function is constant) using the 
estimated parameters based on the baseline hazard functions of  the population for two 
treatment groups, respectively. 
- Determine the time in the study, tstudy, by subtracting the time of being randomized 
from the whole time period of trial, t. 
- Compare time from trial start to theoretical event, 𝑡𝑡ℎ𝑒𝑜𝑟𝑦, with the time in the study, 
𝑡𝑠𝑡𝑢𝑑𝑦. We denote the time and indicator variables as follows: 
𝑡𝑜𝑏𝑠 [𝑖] = min (𝑡𝑡ℎ𝑒𝑜𝑟𝑦[𝑖], 𝑡𝑠𝑡𝑢𝑑𝑦[𝑖]) 
𝐸𝑣𝑒𝑛𝑡[𝑖] = �0 𝑖𝑓 𝑡𝑡ℎ𝑒𝑜𝑟𝑦[𝑖] >  𝑡𝑠𝑡𝑢𝑑𝑦[𝑖]1 𝑖𝑓 𝑡𝑡ℎ𝑒𝑜𝑟𝑦[𝑖] ≤ 𝑡𝑠𝑡𝑢𝑑𝑦[𝑖]  
For each of the three NSAB trials, we separately generated 1,000 simulated data sets with 
sample size that was equal to that for each of the three trials. 
 
3.4.2 The Log-rank Test  
The log-rank test which takes the whole follow up period into account is the most popular 
method of comparing the survival of groups.  It has the considerable advantage that it does not 
require that one know the shape of the survival curve or the distribution of survival times.  The 
log-rank test is used to test the null hypothesis that there is no difference between the populations 
in the probability of an event at any time point.  The test statistic is calculated as follows: 
𝜒2(𝑙𝑜𝑔𝑟𝑎𝑛𝑘) = (𝑂1−𝐸1)2
𝐸1
+ (𝑂2−𝐸2)2
𝐸2
, where 𝑂1 and 𝑂2 are the total numbers of observed events in 
groups 1 and 2, respectively, and 𝐸1 and 𝐸2 the total numbers of expected events.   
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If the null hypothesis is true, we expect 𝑒𝑖𝑗 = 𝑛𝑖𝑗 ∗ 𝑑𝑗𝑛𝑗, where 𝑛𝑖𝑗 is the number at risk just 
prior to time j in group i= 1, 2; 𝑛𝑗  is the total number of cases that are at risk just prior to time j; 
𝑑𝑗 is the total number of events at time j in both groups.  The total expected number of events for 
a group is the sum of the expected number of events at the time of each event.  Then the test 
statistic is compared with the chi-square distribution with 1 degree of freedom and the 
corresponding p-value is obtained.  
For each of the simulated data, we perform the log-rank test and record the p-value for 
the two-sided hypothesis test for the difference between treatment groups. 
 
3.4.3 The Randomization Test  
Let Ω denote the size of the reference set and S be the test statistic of interest, which can be any 
measure of the difference between the treatment groups.  Define 𝑆𝑤 to be the value of S for 
sequence w, 𝑤 = 1, … ,Ω and 𝑆𝑜𝑏𝑠 to be the given observed test statistic based on the sequence 
𝑤𝑜𝑏𝑠 actually used.  Let W record realizations of particular randomization sequences; W has a 
probability distribution depending on the particular randomization procedure employed.  Then 
the two-sided p value of the permutation test is given by 
                       𝑝 = ∑ 𝐼(|𝑆𝑤 −  𝑆̅| ≥ |𝑆𝑜𝑏𝑠 −  𝑆̅|)Pr (𝑊 = 𝑤)Ω𝑤=1 ,                                    (1) 
where 𝑆̅ = ∑ 𝑆𝑤Pr (𝑊 = 𝑤)Ω𝑤=1  and 𝐼(. ) is the indicator function.  
However, it is practically infeasible to computation the equation (1) especially if the 
sample size and number of randomized groups is large.  Using the NSABP B-24 trail as the 
example, the sample size is 1801 and the all possible ways of assigning equal number of 
participants to each group would be 
1801!
900!901!.  It is therefore usually to use Monte Carlo sampling 
from all possible assignments to estimate the true permutation test p value, that is as a 
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randomization test.  Let 𝑆𝑚,𝑚 = 1,2, … ,𝑀, denotes the mth test statistic randomly sampled from 
the all possible assignments evaluated under the condition that the order of patient’s visits, 
responses, and covariate values are all fixed.  Then, a two-sided Monte Carlo p value for a test 
that rejects for large values of 𝑆𝑜𝑏𝑠 is 
                                   ?̂? = 1+∑ 𝐼(|𝑆𝑚−?̅?|≥|𝑆𝑜𝑏𝑠−?̅?|)𝑀𝑚=1
𝑀+1
, 𝑆̅ = ∑ 𝑆𝑚
𝑀
𝑀
𝑚=1                                     (2) 
For each of the simulated data, the two-sided p-value of for the randomization test was 
estimated by Monte Carlo sampling (2) with M=1,000 replications under the condition that the 
order of patient’s visits, responses, and covariate values are all fixed.   
To compare the performances of these two statistical tests for trials employing biased-
coin minimization, we compared the proportions of the 1,000 simulations for which we obtain a 
p-value<0.05 from the log-rank test to that obtained from the randomization test to determine 
whether the nominal significance level (5%) is maintained.  We also assess the agreement on the 
significance/ non-significance of p-values from two tests in the 1,000 simulations.  Further, in 
order to investigate the influence of effect size on the comparison of results from the two tests, 
we carried out simulations using parameters from each trial with four scenarios of hazard ratio: 
0.50, 0.60, 0.80, and 0.90 under statistical power of 0.8. 
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4.0 RESULTS 
4.1 BALANCING PROPERTIES OF BIASED-COIN MINIMIZATION 
4.1.1 The Overall Treatment Imbalance 
Figures 2, 3 and 4 display the histograms of the overall treatment imbalance over 1,000 
simulated treatment allocations for NSABP B-24, B-28 and P-1 comparing different scenarios of 
treatment allocation imbalance tolerance levels and assignment probabilities of the biased-coin in 
the minimization algorithm.  The mean and its 95% confidence interval of the overall treatment 
imbalance under the different scenarios from 1,000 simulated treatment allocations for three 
trials are presented in Tables 4.1.1.  The mean overall imbalance between the two treatment 
groups does not exceed 6 for any of the scenarios as the minimization randomization is applied.  
This compared with simple randomization where the mean level of overall treatment imbalance 
is greater than 33 in B-24 trial, 43 in B-28 trial, and 90 in P-1 trial.  Such results are shown in 
both the conditions when the clinical site is not included as one of the stratification factors (Table 
4.1.1a) and when the clinical site is included (Table 4.1.1b).   
 The average overall treatment imbalance and its variability increase as the treatment 
allocation imbalance tolerance level increases and these parameters decrease as the assignment 
probability of the biased-coin increases.  These results are as expected from the definition of the 
minimization procedure, in that as the less the treatment assignments are left to be randomly 
chosen, the overall treatment imbalance would become lower.  In the condition that the clinical 
site is not included as one of the stratification factors, the average overall treatment imbalance 
increases up to1.27 as the treatment assignment imbalance tolerance level increases from 2 to 4, 
and it decreases up to 2.75 as the assignment probabilities of the biased-coin increases from 0.6 
to 0.8.  In the B-24 trial, when the biased-coin probability is 0.6, the average overall treatment 
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imbalance only increases 0.42 as the treatment assignment imbalance tolerance level increases 
from 2 to 3 yet, it increases 1.03as the treatment assignment imbalance tolerance level increases 
from 2 to 4.  When the biased-coin probability is 0.7 or 0.8, the average overall treatment 
imbalance increases 0.64 and 0.58 as the treatment allocation imbalance tolerance level increases 
from 2 to 3 and the increase becomes 1.27 and 1.18 as the treatment allocation imbalance 
tolerance level increases from 2 to 4.  However, in the B-28 and P-1 trials where the sample size 
is larger, the increase in the average overall treatment imbalance along with the increase in 
imbalance tolerance level is minimal.  The increase exceeds 0.30 only when the biased-coin 
probability is greater than 0.7 and the treatment allocation imbalance tolerance level increases 
from 2 to 4.  Also, the maximum increase does not surpass 0.40 in the B-28 or P-1 trials.  The 
decrease in the average overall treatment imbalance resulting from the increase in the biased-
coin probability is greater than 1.25 no matter what value of the treatment allocation imbalance 
tolerance level is in three trials and the magnitude of the decrease raises as the sample size is 
larger.  For most scenarios, the inclusion of clinical site as a stratification factor slightly 
increases the overall treatment imbalance.  The maximum value of the average overall treatment 
imbalance is 5.42 in B-24 trial yet the average overall treatment imbalance is below 5 in B-28 
and P-1 trials for the biased-coin probability of 0.6.   
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(a) When clinical site is not considered as one of the stratification factors  
 
(b) When clinical site is considered as one of the stratification factors  
 
Figure 2.  The histograms of the overall treatment imbalance over 1,000 simulated 
treatment allocations for NSABP B-24 Trial 
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(a) When clinical site is not considered as one of the stratification factors  
 
(b) When clinical site is considered as one of the stratification factors  
 
Figure 3.  The histograms of the overall treatment imbalance over 1,000 simulated 
treatment allocations for NSABP B-28 Trial 
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(a) When clinical site is not considered as one of the stratification factors  
 
(b) When clinical site is considered as one of the stratification factors  
 
Figure 4.  The histograms of the overall treatment imbalance over 1,000 simulated 
treatment allocations for NSABP P-1 Trial 
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Table 4.1.1a The mean overall treatment imbalance from 1,000 simulated treatment 
allocations of complete set of trials when clinical site is not included as one of the 
stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801)  B-28 trial (n=3,060)  P-1 trial (n=13,388) 
Mean 95% CI  Mean 95% CI  Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 4.44 (4.22, 4.66)  3.92 (3.71, 4.13)  4.06 (3.85, 4.27) 
0.7 2.91 (2.77, 3.04)  2.04 (1.92, 2.15)  2.09 (1.97, 2.20) 
0.8 2.47 (2.37, 2.58)  1.43 (1.35, 1.52)  1.41 (1.33, 1.49) 
Treatment assignment imbalance tolerance level=3 
0.6 4.86 (4.63, 5.08)  4.02 (3.82, 4.22)  4.26 (4.04, 4.48) 
0.7 3.55 (3.40, 3.71)  2.16 (2.04, 2.28)  2.27 (2.15, 2.39) 
0.8 3.05 (2.92, 3.18)  1.56 (1.47, 1.65)  1.51 (1.42, 1.60) 
Treatment assignment imbalance tolerance level=4 
0.6 5.47 (5.21, 5.73)  4.08 (3.87, 4.29)  4.37 (4.15, 4.59) 
0.7 4.18 (3.99, 4.37)  2.41 (2.29, 2.54)  2.39 (2.26, 2.51) 
0.8 3.65 (3.49, 3.81)  1.76 (1.65, 1.86)  1.75 (1.66, 1.85) 
Simple randomization 
0.5 34.54 (32.99, 36.10)  43.68 (41.66, 45.70)  97.38 (92.90, 101.86) 
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Table 4.1.1b The mean overall treatment imbalance from 1,000 simulated treatment 
allocations of complete set of trials when clinical site is included as one of the stratification 
factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801)  B-28 trial (n=3,060)  P-1 trial (n=13,388) 
Mean 95% CI  Mean 95% CI  Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 4.90 (4.67, 5.15)  4.18 (3.96, 4.40)  4.42 (4.19, 4.65) 
0.7 3.01 (2.87, 3.15)  2.12 (2.00, 2.24)  2.23 (2.11, 2.35) 
0.8 2.49 (2.39, 2.60)  1.59 (1.50, 1.68)  1.44 (1.35, 1.53) 
Treatment assignment imbalance tolerance level=3 
0.6 5.03 (4.80, 5.27)  4.23 (4.01, 4.45)  4.69 (4.44, 4.93) 
0.7 3.44 (3.29, 3.60)  2.26 (2.14, 2.38)  2.50 (2.36, 2.63) 
0.8 2.74 (2.62, 2.87)  1.66 (1.57, 1.76)  1.69 (1.59, 1.78) 
Treatment assignment imbalance tolerance level=4 
0.6 5.42 (5.16, 5.68)  4.46 (4.23, 4.69)  4.60 (4.36, 4.84) 
0.7 3.98 (3.80, 4.16)  2.41 (2.28, 2.54)  2.53 (2.40, 2.66) 
0.8 3.32 (3.17, 3.46)  1.88 (1.78, 1.98)  1.77 (1.67, 1.87) 
Simple randomization 
0.5 35.18 (33.60, 36.75)  42.75 (40.69, 44.80)  87.29 (83.34, 91.23) 
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4.1.2 The Treatment Imbalance within Stratification Factors 
The treatment imbalance within stratification factors was assessed by two measurements over 
1000 simulated treatment allocations of the complete set for each of the three trials: 1) the 
proportion for which the maximum treatment imbalance in any stratification factor is greater 
than 4; and 2) the mean maximum imbalance within the levels of the stratification factors.  The 
results of these two balancing properties for three trials are present below separately.  
4.1.2.1 NSABP B-24 trial 
Table 4.1.2.1 provides the results of simulations for the effect of stratification in the B-24 trial.  
Age, defined in two levels, was the only stratification factor used in B-24.  The results from the 
simulations show that the proportion for which the maximum imbalance within either age strata 
being greater than 4 in 1,000 simulated treatment allocations dramatically decreases to below 
0.50 when the biased-coin minimization is applied whereas the proportion is around 0.98 when 
the simple randomization is applied.  The mean maximum treatment imbalance within the 2 
levels of age decreases from 34 as simple randomization is applied to less than 6 as the 
minimization randomization is applied.  Although the inclusion of clinical sited as the 
stratification factor would increase the treatment imbalance within the stratification factor, the 
proportion for which the maximum imbalance in one of the age strata being greater than 4 in 
1,000 simulated treatment allocation is still below 0.6 and the mean maximum imbalance within 
the 2 levels of age is less than 5.50.  The proportion for which the maximum imbalance in one of 
the age strata being greater than 4 and the maximum imbalance within the 2 levels of age 
decreases as the assignment probabilities of the biased-coin increases.   
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Table 4.1.2.1  The proportion of 1,000 simulations for which the maximum treatment imbalance within either of the two-level 
stratification factor of age in B-24 trial, is greater than 4 and the mean maximum treatment imbalance within either of the two 
levels of age for the B-24 trial simulations. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
Clinical Site is not included as 
one of the stratification factors 
Clinical Site is included as 
one of the stratification factors 
Proportion for which 
the maximum 
imbalance > 4 
Mean 95% CI 
Proportion for which 
the maximum 
imbalance is > 4 
Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.313 4.32 (4.15, 4.51) 0.472 4.85 (4.66, 5.03) 
0.7 0.082 2.78 (2.68, 2.88) 0.174 3.01 (2.90, 3.11) 
0.8 0.017 2.29 (2.21, 2.36) 0.056 2.44 (2.36, 2.51) 
Treatment assignment imbalance tolerance level=3 
0.6 0.410 4.90 (4.72, 5.08) 0.541 5.17 (4.99, 5.34) 
0.7 0.139 3.44 (3.33, 3.54) 0.265 3.53 (3.41, 3.65) 
0.8 0.032 3.07 (2.99, 3.15) 0.112 2.75 (2.66, 2.84) 
Treatment assignment imbalance tolerance level=4 
0.6 0.489 5.48 (5.29, 5.66) 0.572 5.49 (5.30, 5.68) 
0.7 0.260 4.02 (3.91, 4.14) 0.350 3.91 (3.79, 4.03) 
0.8 0.105 3.50 (3.41, 3.59) 0.244 3.39 (3.29, 3.49) 
Simple randomization 
0.5 0.982 33.81 (32.66, 34.96) 0.986 34.58 (33.46, 35.70) 
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4.1.2.2 NSABP B-28 trial 
Table 4.1.2.2a and 4.1.2.2b display the results of simulations to assess the effect of stratification 
in the B-28 Trial.  In this study there were three stratification factors including number of nodes 
(3 levels), Tamoxifen administration (2 levels) and type of surgery (2 levels).  The results 
indicate that as the assignment probabilities of the biased-coin increases from 0.6 to 0.7 or 0.8, 
the minimum reduction in the proportion of the maximum imbalance in each stratification factor 
greater than 4 in 1,000 simulated treatment allocation is 0.28 and 0.40, respectively; while the 
minimum reduction in the mean level of maximum imbalance within the levels of these 
stratification factors could be 2.18 and 2.99, respectively.  Number of nodes, a factor with three 
levels, has higher mean level of maximum imbalance within the levels of these stratification 
factors than the other two factors, which possessed two levels.  This is true regardless of the 
treatment allocation imbalance tolerance level or the assignment probability of the biased-coin 
but the difference in the mean level of maximum imbalance within the levels of stratification 
factors is quite small if simple randomization is performed.  Also, the decrease in treatment 
imbalance within stratification factors resulting from larger biased-coin probability is larger for 
the factor with more levels.  As expected, the inclusion of clinical site as the stratification factor 
increases the treatment imbalance within the stratification factors.  Although the proportion of 
the maximum imbalance in each stratification factor greater than 4 is higher than 0.50 when 
considering a biased-coin probability of 0.6, the mean maximum imbalance within any levels of 
the stratification factors is still below 7. 
4.1.2.3 NSABP P-1 trial   
The results of simulations to assess the effect of stratification in the P-1 trial are shown in Table 
4.1.2.3a and Table 4.1.2.3b.  There were four stratification factors used in the P-1 study 
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including age (3 levels), race (3 levels), history of LCIS (2 levels) and breast cancer relative risk 
(3 levels).  The mean maximum treatment imbalance within any levels of the stratification 
factors decreases from above 90 as simple randomization is applied to less than 8 as the 
minimization randomization is applied.  When considering a biased-coin probability above 0.7, 
the mean maximum treatment imbalance within any levels of the stratification factors would be 
less than 5.  Again, the maximum imbalance within the levels of these stratification factors for 
the factors that have 3 levels is higher than the factor with 2 levels and the decrease in treatment 
imbalance within stratification factors resulting from larger biased-coin probability is larger for 
the factor with more levels. 
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Table 4.1.2.2a  The proportion of 1,000 simulations for which the maximum imbalance within any level of the three stratification 
factors in B-28 trial is greater than 4 and the mean maximum imbalance within any levels of three stratification factors for the B-28 
trial simulations  when clinical site is not included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
Number of nodes 
(3 levels) 
Tamoxifen administration 
(2 levels) 
Type of Surgery 
(2 levels) 
Proportion 
for which 
the 
maximum 
imbalance 
is > 4 
Mean 95% CI 
Proportion 
for which 
the 
maximum 
imbalance 
is > 4 
Mean 95% CI 
Proportion 
for which 
the 
maximum 
imbalance 
is > 4 
Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.61 6.29 (6.07, 6.51) 0.58 5.14 (4.93, 5.35) 0.44 5.10 (4.89, 5.30) 
0.7 0.15 3.46 (3.35, 3.57) 0.19 2.75 (2.64, 2.85) 0.11 2.74 (2.63, 2.85) 
0.8 0.03 2.41 (2.33, 2.48) 0.05 1.93 (1.86, 2.01) 0.01 1.95 (1.87, 2.03) 
Treatment assignment imbalance tolerance level=3 
0.6 0.63 6.41 (6.21, 6.62) 0.58 5.19 (4.99, 5.38) 0.45 5.35 (5.14, 5.56) 
0.7 0.18 3.49 (3.37, 3.60) 0.22 2.89 (2.78, 3.00) 0.11 2.86 (2.75, 2.97) 
0.8 0.04 2.72 (2.63, 2.80) 0.09 2.20 (2.12, 2.29) 0.02 2.13 (2.04, 2.21) 
Treatment assignment imbalance tolerance level=4 
0.6 0.64 6.77 (6.54, 7.00) 0.62 5.42 (5.21, 5.63) 0.45 5.51 (5.28, 5.74) 
0.7 0.27 3.80 (3.67, 3.92) 0.30 3.24 (3.12, 3.36) 0.17 3.15 (3.03, 3.27) 
0.8 0.09 3.02 (2.92, 3.11) 0.12 2.41 (2.32, 2.50) 0.05 2.42 (2.33, 2.52) 
Simple randomization 
0.5 0.997 43.38 (41.86, 44.90) 0.992 43.77 (42.10, 45.44) 0.995 43.16 (41.77, 44.55) 
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Table 4.1.2.2b  The proportion of 1,000 simulations for which the maximum imbalance within any level of the three 
stratification factors in B-28 trial is greater than 4 and the mean maximum imbalance within any levels of three stratification factors 
for the B-28 trial simulations when clinical site is included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
Number of nodes 
(3 levels) 
Tamoxifen administration 
(2 levels) 
Type of surgery 
(2 levels) 
Proportion 
for which 
the 
maximum 
imbalance 
is > 4 
Mean 95% CI 
Proportion 
for which 
the 
maximum 
imbalance 
is > 4 
Mean 95% CI 
Proportion 
for which 
the 
maximum 
imbalance 
is > 4 
Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.64 6.75 (6.52, 6.97) 0.60 5.39 (5.18, 5.59) 0.48 5.48 (5.26, 5.69) 
0.7 0.18 3.59 (3.48, 3.71) 0.22 2.85 (2.74, 2.96) 0.11 2.83 (2.72, 2.94) 
0.8 0.04 2.60 (2.51, 2.68) 0.07 2.11 (2.03, 2.19) 0.02 2.12 (2.04, 2.20) 
Treatment assignment imbalance tolerance level=3 
0.6 0.64 6.78 (6.56, 7.00) 0.65 5.75 (5.54, 5.97) 0.51 5.55 (5.35, 5.76) 
0.7 0.21 3.71 (3.59, 3.83) 0.28 3.07 (2.95, 3.19) 0.14 3.03 (2.91, 3.15) 
0.8 0.07 2.80 (2.70, 2.89) 0.09 2.24 (2.15, 2.32) 0.04 2.33 (2.24, 2.42) 
Treatment assignment imbalance tolerance level=4 
0.6 0.67 6.98 (6.76, 7.19) 0.65 5.82 (5.60, 6.04) 0.54 5.89 (5.67, 6.11) 
0.7 0.27 4.03 (3.91, 4.15) 0.32 3.34 (3.21, 3.46) 0.18 3.35 (3.23, 3.47) 
0.8 0.12 3.10 (3.00, 3.20) 0.15 2.55 (2.46, 2.64) 0.04 2.46 (2.36,2.55 ) 
Simple randomization 
0.5 0.996 42.02 (40.50, 43.53) 0.986 42.18 (40.48, 43.88) 0.987 43.95 (42.45, 45.45) 
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Table 4.1.2.3a  The mean maximum imbalance within any levels of the four stratification factors in the P-1 trial over 1,000 
simulations of treatment allocations when clinical site is not included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
Age 
(3 levels) 
Race 
(3 levels) 
History of LCIS 
(2 levels) 
Breast cancer relative risk 
(3 levels) 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 7.23 (6.99, 7.46) 7.09 (6.86, 7.32) 5.66 (5.45, 5.88) 7.09 (6.86, 7.32) 
0.7 3.78 (3.67, 3.90) 3.68 (3.57, 3.79) 2.96 (2.85, 3.06) 3.66 (3.54, 3.78) 
0.8 2.59 (2.51, 2.67) 2.58 (2.50, 2.65) 2.03 (1.95, 2.11) 2.50 (2.42, 2.58) 
Treatment assignment imbalance tolerance level=3 
0.6 7.28 (7.05, 7.52) 7.33 (7.09, 7.57) 5.93 (5.71, 6.15) 7.27 (7.04, 7.50) 
0.7 4.07 (3.94, 4.19) 4.00 (3.88, 4.13) 3.10 (2.98, 3.22) 3.84 (3.72, 3.96) 
0.8 2.91 (2.82, 3.00) 2.86 (2.78, 2.95) 2.17 (2.08, 2.26) 2.86 (2.77, 2.95) 
Treatment assignment imbalance tolerance level=4 
0.6 7.38 (7.14, 7.62) 7.66 (7.42, 7.90) 5.92 (5.69, 6.14) 7.45 (7.22, 7.69) 
0.7 4.23 (4.10, 4.36) 4.15 (4.03, 4.28) 3.34 (3.21, 3.46) 4.19 (4.06, 4.32) 
0.8 3.19 (3.10, 3.29) 3.21 (3.11, 3.30) 2.48 (2.38, 2.57) 3.09 (2.99, 3.18) 
Simple randomization 
0.5 90.97 (88.55, 93.39) 96.37 (92.08, 100.66)  96.92 (92.68, 101.17) 93.25 (90.41, 96.08) 
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Table 4.1.2.3b  The mean maximum imbalance within any levels of the four stratification factors in P-1 trial over 1,000 
simulated treatment allocations for complete set of trial when clinical site is included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
Age 
(3 levels) 
Race 
(3 levels) 
History of LCIS 
(2 levels) 
Breast cancer relative risk 
(3 levels) 
Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 7.73 (7.49, 7.97) 7.70 (7.46, 7.94) 6.13 (5.90, 6.36) 7.71 (7.46, 7.95) 
0.7 3.96 (3.83, 4.08) 4.02 (3.90, 4.15) 3.15 (3.03, 3.27) 4.03 (3.90, 4.16) 
0.8 2.76 (2.67, 2.85) 2.81 (2.72, 2.90) 2.14 (2.05, 2.23) 2.79 (2.70, 2.88) 
Treatment assignment imbalance tolerance level=3 
0.6 7.98 (7.74, 8.23) 7.84 (7.60, 8.09) 6.42 (6.18, 6.67) 7.94 (7.69, 8.18) 
0.7 4.23 (4.10, 4.35) 4.34 (4.21, 4.47) 3.40 (3.27, 3.53) 4.20 (4.07, 4.33) 
0.8 3.01 (2.92, 3.10) 3.06 (2.97, 3.16) 2.34 (2.25, 2.43) 2.97 (2.88, 3.07) 
Treatment assignment imbalance tolerance level=4 
0.6 8.18 (7.92, 8.45) 7.87 (7.62, 8.11) 6.55 (6.30, 6.79) 8.11 (7.85, 8.37) 
0.7 4.42 (4.29, 4.55) 4.38 (4.24, 4.51) 3.46 (3.34, 3.59) 4.42 (4.28, 4.55) 
0.8 3.23 (3.14, 3.33) 3.19 (3.09, 3.29) 2.49 (2.39, 2.58) 3.10 (3.00, 3.19) 
Simple randomization 
0.5 86.21 (83.88, 88.54) 86.56 (82.81, 90.32)  87.91 (84.15, 91.67) 86.98 (84.35, 89.60) 
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4.1.3 The Treatment Imbalance within Clinical Site   
The proportion of clinical sites that exhibited an imbalance by treatment arm that was 5 or 
greater was used to assess the likelihood of obtaining a substantial treatment imbalance within 
site.  Only those sites that randomized at least 15 patients were included in this assessment.  The 
findings from the 1,000 simulated treatment allocations are shown in both the conditions when 
the clinical site is not included as one of the stratification factors (Table 4.1.3a) and when the 
clinical site is included (Table 4.1.3b).  
When the clinical site is not considered as one of the stratification factors, neither change 
in the level of imbalance tolerance or change in the treatment allocation probability result in any 
noticeable change in the proportion of sites having a within-site treatment imbalance of 5 or 
greater and the results for all scenarios are close to that seen when just simple randomization is 
applied.  However, the proportion of sites having a within-site treatment imbalance of 5 or 
greater seems to increase as the sample size of trial is larger.  The proportion of sites having a 
within-site treatment imbalance of 5 or greater is about 0.28 for B-24 trial (n=1,801) and about 
0.56 for P-1 trial (n=13,388).  On the other hand, when clinical site is included as one of the 
stratification factors, an increase in the treatment allocation probability dramatically decreases 
the within-site imbalance as expected.  The proportion of sites having a within-center treatment 
imbalance of 5 or greater decreases to less than 0.20 for B-24 and B-28 trials and less than 0.40 
for P-1 trial even in the situation of 0.6 biased-coin probability and the proportion would be more 
minimal when the biased-coin probability above 0.7 is considered. 
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Table 4.1.3a The mean proportion of sites with more than 15 patients for whom the 
absolute difference between the numbers of patients in two treatment groups at that site is 
5 or greater for each trial over 1,000 simulated treatment allocations for complete set of 
trials when clinical site is not included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.280 (0.275, 0.285) 0.320 (0.316, 0.324)  0.557 (0.555, 0.560) 
0.7 0.275 (0.270, 0.280) 0.319 (0.315, 0.323)  0.552 (0.549, 0.555) 
0.8 0.275 (0.270, 0.280) 0.315 (0.312, 0.319)  0.552 (0.550, 0.555) 
Treatment assignment imbalance tolerance level=3 
0.6 0.273 (0.268, 0.278) 0.321 (0.318, 0.325)  0.555 (0.552, 0.558) 
0.7 0.271 (0.266, 0.276) 0.322 (0.318, 0.325)  0.553 (0.550, 0.556) 
0.8 0.273 (0.268, 0.278) 0.322 (0.318, 0.325)  0.552 (0.549, 0.555) 
Treatment assignment imbalance tolerance level=4 
0.6 0.275 (0.270, 0.281) 0.320 (0.316, 0.324)  0.556 (0.553, 0.559) 
0.7 0.276 (0.271, 0.281) 0.321 (0.317, 0.325)  0.555 (0.552, 0.558) 
0.8 0.272 (0.267, 0.277) 0.319 (0.315, 0.323)  0.552 (0.549, 0.555) 
Simple randomization 
0.5 0.278 (0.273, 0.283) 0.326 (0.322, 0.329)  0.559 (0.556, 0.561) 
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Table 4.1.3b The mean proportion of sites with more than 15 patients for whom the 
absolute difference between the numbers of patients in two treatment groups at that center 
is 5 or greater for each trial over 1,000 simulated treatment allocations for complete set of 
trials when clinical site is included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.134 (0.130, 0.138) 0.212 (0.209, 0.216) 0.359 (0.356, 0.362) 
0.7 0.040 (0.038, 0.042) 0.079 (0.077, 0.081) 0.123 (0.121, 0.125) 
0.8 0.009 (0.008, 0.011) 0.021 (0.019, 0.022) 0.031 (0.030, 0.032) 
Treatment assignment imbalance tolerance level=3 
0.6 0.149 (0.145, 0.153) 0.217 (0.214, 0.220) 0.365 (0.363, 0.368) 
0.7 0.058 (0.055, 0.061) 0.093 (0.091, 0.095) 0.137 (0.135, 0.139) 
0.8 0.020 (0.018, 0.022) 0.033 (0.031, 0.034) 0.042 (0.041, 0.043) 
Treatment assignment imbalance tolerance level=4 
0.6 0.168 (0.163, 0.172) 0.222 (0.219, 0.226) 0.371 (0.368, 0.373) 
0.7 0.084 (0.081, 0.087) 0.109 (0.107, 0.112) 0.154 (0.152, 0.156) 
0.8 0.043 (0.040, 0.045) 0.048 (0.047, 0.050) 0.059 (0.058, 0.060) 
Simple randomization 
0.5 0.277 (0.271, 0.282) 0.323 (0.319, 0.327) 0.558 (0.555, 0.561) 
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4.1.4 Evaluation of the Effects from Different Dimensions in a Clinical Trial on the 
Balancing Properties  
To further  describe the impact that the different dimensions of clinical trial design (sample size, 
number of stratification factors and number of levels within a stratification factor) have on the 
balancing properties, we present a series of simulations of treatment allocation for first 1,801 
patients, first 3,060 patients, and all patients in P-1 trial considering four sets of variables, 
containing one, two, three and all four of the stratification factors in P-1 trial for the different 
scenarios of imbalance tolerance and bias-coin assignment probabilities.  In order to assess the 
sole effect from different dimensions of trial design on treatment balance, results are compared 
across different scenarios within one dimension, controlling the other two dimensions.   
First, we explore the effect of different numbers of levels within stratification factors on 
the overall treatment imbalance.  The results of the mean overall treatment imbalance 
considering one stratification factor (Table 4.1.4.1a and Table 4.1.4.1b) and three stratification 
factors (Table 4.1.4.1c and Table 4.1.4.1d) with different numbers of stratification factor levels 
across different sample sizes are summarized in Table 4.1.4.1.  When controlling for the number 
of stratification factors and the number of levels in a stratification factor, the result shows that 
the sample size does not have a significantly consistent effect on the overall treatment imbalance. 
When the number of stratification factor is the same, the overall treatment imbalance would 
increase when there are more levels within stratification factor.  We also explore the effect of 
different numbers of stratification factors on the overall treatment imbalance .  The results from 
the scenarios considering different numbers of stratification factors (2 factors versus 4 factors) 
displayed in the table 4.1.4.2a – 4.1.4.2b show that more stratification factors are considered 
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would decrease the overall treatment imbalance.  Further, such relationships are both shown in 
the treatment allocation with different sample size.  
In light of the result that the change in treatment imbalance within clinical site is quite 
small when clinical site is not included as one of the stratification factors, we consider only the 
scenario of including clinical site as one of the stratification factors while investigating the effect 
from different dimensions on the treatment imbalance within center.  Tables 4.1.4.3 shows the 
mean proportion of clinical sites with more than 15 patients for whom the treatment imbalance at 
that site is 5 or greater considering one stratification factor (Tables 4.1.4.3a) and three 
stratification factors (Tables 4.1.4.3b) with different numbers of stratification factor levels across 
different sample sizes.  The magnitude of the within-site treatment imbalance is smaller as the 
biased-coin probability is increased; and, when the treatment assignment probability is greater 
than 0.6, sample size has little effect on the magnitude of within-site treatment imbalance. Also, 
number of stratification factor levels has a negligible effect on the treatment imbalance within 
clinical site in all scenarios.  Lastly, the result in Table 4.1.4.4 shows that more treatment 
imbalance within clinical site would be introduced as more stratification factors are considered to 
be balanced. 
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Table 4.1.4.1a The comparison of the mean overall treatment imbalance for each dataset over 
1,000 simulated treatment allocations for one stratification factor with two or three levels when 
clinical site is not included as one of the stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
1 factor 
with 2 
levels 
Treatment assignment imbalance tolerance level=2 
0.6 4.42 (4.21, 4.64) 4.27 (4.05, 4.49) 4.50 (4.27, 4.73) 
0.7 2.95 (2.81, 3.08) 2.80 (2.66, 2.94) 2.86 (2.71, 3.00) 
0.8 2.52 (2.42, 2.63) 2.10 (1.99, 2.21) 2.25 (2.14, 2.37) 
Treatment assignment imbalance tolerance level=3 
0.6 4.99 (4.76, 5.23) 4.99 (4.75, 5.23) 5.05 (4.80, 5.30) 
0.7 3.48 (3.32, 3.63) 3.47 (3.30, 3.63) 3.54 (3.37, 3.71) 
0.8 3.04 (2.91, 3.17) 3.12 (2.97, 3.27) 3.02 (2.87, 3.16) 
Treatment assignment imbalance tolerance level=4 
0.6 5.25 (5.01, 5.50) 5.40 (5.13, 5.67) 5.44 (5.19, 5.69) 
0.7 4.07 (3.89, 4.24) 3.99 (3.81, 4.17) 3.88 (3.69, 4.06) 
0.8 3.71 (3.54, 3.87) 3.60 (3.44, 3.77) 3.48 (3.32, 3.65) 
1 factor 
with 3 
levels 
Treatment assignment imbalance tolerance level=2 
0.6 5.81 (5.53, 6.09) 5.52 (5.24, 5.80) 5.39 (5.12, 5.67) 
0.7 3.62 (3.46, 3.78) 3.34 (3.18, 3.51) 3.53 (3.37, 3.70) 
0.8 2.92 (2.79, 3.05) 2.82 (2.67, 2.96) 2.79 (2.65, 2.93) 
Treatment assignment imbalance tolerance level=3 
0.6 6.28 (5.99, 6.57) 6.13 (5.83, 6.43) 6.18 (5.87, 6.48) 
0.7 4.36 (4.16, 4.56) 4.27 (4.07, 4.47) 4.12 (3.92, 4.32) 
0.8 3.70 (3.54, 3.86) 3.64 (3.47, 3.82) 3.64 (3.47, 3.81) 
Treatment assignment imbalance tolerance level=4 
0.6 6.81 (6.48, 7.13) 6.47 (6.16, 6.78) 6.38 (6.08, 6.68) 
0.7 5.16 (4.93, 5.39) 4.71 (4.49, 4.93) 4.83 (4.60, 5.06) 
0.8 4.35 (4.15, 4.55) 4.49 (4.28, 4.70) 4.51 (4.31, 4.72) 
50 
Table 4.1.4.1b The comparison of the mean overall treatment imbalance for each dataset over 
1,000 simulated treatment allocations for one stratification factor with two or three levels when 
clinical site is included as one of the stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
1 factor 
with 2 
levels 
Treatment assignment imbalance tolerance level=2 
0.6 4.85 (4.60, 5.09) 4.87 (4.63, 5.10) 5.35 (5.09, 5.62) 
0.7 3.05 (2.91, 3.19) 2.91 (2.76, 3.07) 3.08 (2.92, 3.23) 
0.8 2.36 (2.26, 2.47) 2.17 (2.05, 2.28) 2.19 (2.07, 2.31) 
Treatment assignment imbalance tolerance level=3 
0.6 5.31 (5.06, 5.55) 5.20 (4.94, 5.45) 5.23 (4.96, 5.49) 
0.7 3.45 (3.30, 3.61) 3.38 (3.21, 3.55) 3.37 (3.20, 3.53) 
0.8 2.99 (2.86, 3.12) 2.63 (2.49, 2.76) 2.64 (2.50, 2.78) 
Treatment assignment imbalance tolerance level=4 
0.6 5.49 (5.22, 5.75) 5.56 (5.28, 5.84) 5.90 (5.62, 6.19) 
0.7 3.89 (3.71, 4.06) 3.81 (3.62, 3.99) 3.89 (3.70, 4.08) 
0.8 3.27 (3.13, 3.42) 3.12 (2.97, 3.28) 3.03 (2.88, 3.17) 
1 factor 
with 3 
levels 
Treatment assignment imbalance tolerance level=2 
0.6 6.02 (5.75, 6.29) 6.03 (5.72, 6.33) 6.46 (6.14, 6.77) 
0.7 3.81 (3.64, 3.98) 3.65 (3.47, 3.82) 3.76 (3.57, 3.95) 
0.8 2.81 (2.69, 2.93) 2.81 (2.67, 2.95) 2.81 (2.67, 2.95) 
Treatment assignment imbalance tolerance level=3 
0.6 6.14 (5.84, 6.45) 6.62 (6.30, 6.94) 7.09 (6.74, 7.43) 
0.7 4.38 (4.17, 4.58) 4.10 (3.90, 4.30) 4.13 (3.93, 4.33) 
0.8 3.31 (3.15, 3.46) 3.28 (3.12, 3.45) 3.26 (3.10, 3.41) 
Treatment assignment imbalance tolerance level=4 
0.6 6.79 (6.47, 7.10) 6.66 (6.33, 6.99) 7.01 (6.66, 7.36) 
0.7 4.82 (4.60, 5.03) 4.68 (4.46, 4.90) 4.61 (4.39, 4.82) 
0.8 3.86 (3.68, 4.03) 3.58 (3.40, 3.75) 3.68 (3.50, 3.86) 
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Table 4.1.4.1c The comparison of the mean overall treatment imbalance for each dataset over 
1,000 simulated treatment allocations for three stratification factors with varying levels when 
clinical site is not included as one of the stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
3 factors 
(1 with 2 
levels and 2 
with 3 levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.00 (3.81, 4.19) 4.01 (3.80, 4.22) 4.12 (3.90, 4.33) 
0.7 2.30 (2.19, 2.40) 2.20 (2.08, 2.32) 2.19 (2.07, 2.31) 
0.8 1.73 (1.65, 1.80) 1.63 (1.55, 1.72) 1.56 (1.46, 1.65) 
Treatment assignment imbalance tolerance level=3 
0.6 3.93 (3.73, 4.12) 4.21 (3.99, 4.42) 4.34 (4.11, 4.57) 
0.7 2.37 (2.26, 2.47) 2.24 (2.12, 2.35) 2.36 (2.24, 2.49) 
0.8 1.89 (1.81, 1.98) 1.67 (1.58, 1.77) 1.72 (1.62, 1.82) 
Treatment assignment imbalance tolerance level=4 
0.6 4.06 (3.86, 4.26) 4.23 (4.02, 4.44) 4.35 (4.13, 4.57) 
0.7 2.57 (2.45, 2.68) 2.66 (2.52, 2.79) 2.48 (2.35, 2.61) 
0.8 2.13 (2.03, 2.22) 1.93 (1.83, 2.04) 1.96 (1.86, 2.07) 
3 factors 
 (all with 3 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.27 (4.06, 4.48) 4.42 (4.19, 4.64) 4.55 (4.32, 4.77) 
0.7 2.44 (2.33, 2.56) 2.27 (2.14, 2.40) 2.43 (2.30, 2.55) 
0.8 1.82 (1.75, 1.90) 1.72 (1.62, 1.81) 1.57 (1.48, 1.66) 
Treatment assignment imbalance tolerance level=3 
0.6 4.14 (3.95, 4.33) 4.32 (4.10, 4.53) 4.56 (4.33, 4.78) 
0.7 2.60 (2.48, 2.72) 2.60 (2.47, 2.73) 2.48 (2.35, 2.61) 
0.8 2.05 (1.97, 2.14) 1.88 (1.78, 1.98) 1.90 (1.80, 2.01) 
Treatment assignment imbalance tolerance level=4 
0.6 4.53 (4.31, 4.74) 4.50 (4.27, 4.72) 4.64 (4.40, 4.87) 
0.7 2.71 (2.59, 2.83) 2.75 (2.60, 2.89) 2.72 (2.57, 2.86) 
0.8 2.29 (2.18, 2.39) 2.21 (2.10, 2.33) 2.06 (1.95, 2.17) 
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Table 4.1.4.1d The comparison of the mean overall treatment imbalance for each dataset over 
1,000 simulated treatment allocations for three stratification factors with varying levels when 
clinical site is included as one of the stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
3 factors 
(1 with 2 
levels and 2 
with 3 levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.04 (3.84, 4.24) 4.36 (4.13, 4.59) 4.62 (4.38, 4.85) 
0.7 2.47 (2.35, 2.58) 2.34 (2.22, 2.46) 2.45 (2.31, 2.58) 
0.8 1.86 (1.78, 1.94) 1.60 (1.51, 1.69) 1.64 (1.55, 1.74) 
Treatment assignment imbalance tolerance level=3 
0.6 4.32 (4.10, 4.54) 4.32 (4.11, 4.52) 4.57 (4.34, 4.79) 
0.7 2.53 (2.41, 2.65) 2.49 (2.36, 2.62) 2.47 (2.33, 2.60) 
0.8 1.95 (1.87, 2.03) 1.80 (1.70, 1.89) 1.83 (1.74, 1.93) 
Treatment assignment imbalance tolerance level=4 
0.6 4.12 (3.92, 4.31) 4.33 (4.12, 4.54) 4.71 (4.46, 4.95) 
0.7 2.68 (2.55, 2.80) 2.70 (2.56, 2.85) 2.73 (2.59, 2.87) 
0.8 2.08 (1.99, 2.17) 1.99 (1.88, 2.10) 2.00 (1.89, 2.11) 
3 factors 
 (all with 3 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.22 (4.02, 4.42) 4.47 (4.24, 4.69) 4.88 (4.63, 5.13) 
0.7 2.57 (2.46, 2.69) 2.48 (2.35, 2.61) 2.57 (2.44, 2.70) 
0.8 2.01 (1.92, 2.09) 1.82 (1.72, 1.92) 1.82 (1.71, 1.92) 
Treatment assignment imbalance tolerance level=3 
0.6 4.49 (4.28, 4.71) 4.42 (4.20, 4.64) 5.13 (4.88, 5.38) 
0.7 2.76 (2.63, 2.88) 2.64 (2.51, 2.78) 2.77 (2.62, 2.91) 
0.8 2.12 (2.02, 2.21) 1.93 (1.82, 2.03) 1.90 (1.80, 2.00) 
Treatment assignment imbalance tolerance level=4 
0.6 4.61 (4.37, 4.84) 4.72 (4.48, 4.95) 5.36 (5.10, 5.62) 
0.7 2.89 (2.76, 3.03) 2.87 (2.72, 3.01) 2.91 (2.77, 3.06) 
0.8 2.27 (2.17, 2.37) 2.17 (2.05, 2.28) 2.27 (2.15, 2.39) 
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Table 4.1.4.2a The comparison of the mean overall treatment imbalance for each dataset over 
1,000 simulated treatment allocations for different numbers of stratification factors when 
clinical site is not included as one of the stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
2 factors 
(both are 
with 3 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.51 (4.29, 4.73) 4.24 (4.03, 4.45) 4.79 (4.54, 5.03) 
0.7 2.75 (2.62, 2.88) 2.54 (2.41, 2.67) 2.63 (2.49, 2.76) 
0.8 2.10 (2.01, 2.19) 1.77 (1.67, 1.87) 1.93 (1.83, 2.03) 
Treatment assignment imbalance tolerance level=3 
0.6 4.26 (4.06, 4.46) 4.75 (4.50, 4.99) 4.95 (4.70, 5.20) 
0.7 3.06 (2.92, 3.20) 2.90 (2.75, 3.05) 2.88 (2.72, 3.03) 
0.8 2.49 (2.38, 2.60) 2.55 (2.42, 2.68) 2.21 (2.10, 2.32) 
Treatment assignment imbalance tolerance level=4 
0.6 4.55 (4.34, 4.77) 4.99 (4.74, 5.25) 5.40 (5.13, 5.67) 
0.7 3.32 (3.17, 3.47) 3.29 (3.12, 3.45) 3.50 (3.33, 3.66) 
0.8 2.71 (2.59, 2.83) 2.58 (2.46, 2.71) 2.66 (2.53, 2.79) 
4 factors 
 (3 with 3 
levels and 1 
with 2 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.02 (3.82, 4.22) 3.68 (3.49, 3.88) 4.06 (3.85, 4.27) 
0.7 2.29 (2.19, 2.40) 2.13 (2.01, 2.24) 2.09 (1.97, 2.20) 
0.8 1.64 (1.57, 1.71) 1.43 (1.34, 1.52) 1.41 (1.33, 1.49) 
Treatment assignment imbalance tolerance level=3 
0.6 3.98 (3.78, 4.17) 4.20 (3.98, 4.41) 4.26 (4.04, 4.48) 
0.7 2.37 (2.26, 2.48) 2.21 (2.08, 2.33) 2.27 (2.15, 2.39) 
0.8 1.79 (1.71, 1.86) 1.56 (1.47, 1.66) 1.51 (1.42, 1.60) 
Treatment assignment imbalance tolerance level=4 
0.6 4.17 (3.96, 4.39) 3.94 (3.74, 4.15) 4.37 (4.15, 4.59) 
0.7 2.54 (2.43, 2.66) 2.33 (2.20, 2.45) 2.39 (2.26, 2.51) 
0.8 1.89 (1.81, 1.97) 1.63 (1.54, 1.73) 1.75 (1.66, 1.85) 
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Table 4.1.4.2b The comparison of the mean overall treatment imbalance for each dataset over 
1,000 simulated treatment allocations for different numbers of stratification factors when 
clinical site is included as one of the stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
2 factors 
(both are 
with 3 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.48 (4.26, 4.69) 4.78 (4.52, 5.04) 5.35 (5.08, 5.61) 
0.7 2.78 (2.65, 2.90) 2.73 (2.59, 2.87) 2.93 (2.79, 3.08) 
0.8 2.10 (2.00, 2.19) 2.06 (1.95, 2.17) 2.05 (1.94, 2.16) 
Treatment assignment imbalance tolerance level=3 
0.6 4.56 (4.34, 4.78) 4.85 (4.60, 5.09) 5.66 (5.38, 5.94) 
0.7 3.14 (3.00, 3.29) 3.12 (2.96, 3.27) 3.20 (3.04, 3.35) 
0.8 2.48 (2.37, 2.59) 2.30 (2.18, 2.42) 2.49 (2.36, 2.61) 
Treatment assignment imbalance tolerance level=4 
0.6 4.81 (4.57, 5.05) 5.19 (4.92, 5.45) 5.65 (5.37, 5.92) 
0.7 3.49 (3.33, 3.64) 3.33 (3.17, 3.48) 3.31 (3.13, 3.48) 
0.8 2.67 (2.55, 2.79) 2.62 (2.49, 2.76) 2.57 (2.44, 2.71) 
4 factors 
 (3 with 3 
levels and 1 
with 2 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 4.21 (4.00, 4.41) 4.34 (4.12, 4.56) 4.42 (4.19, 4.65) 
0.7 2.27 (2.17, 2.38) 2.24 (2.11, 2.36) 2.23 (2.11, 2.35) 
0.8 1.78 (1.70, 1.85) 1.46 (1.37, 1.55) 1.44 (1.35, 1.53) 
Treatment assignment imbalance tolerance level=3 
0.6 4.18 (3.98, 4.38) 4.02 (3.81, 4.23) 4.69 (4.44, 4.93) 
0.7 2.44 (2.33, 2.54) 2.31 (2.18, 2.43) 2.50 (2.36, 2.63) 
0.8 1.83 (1.75, 1.90) 1.72 (1.62, 1.81) 1.69 (1.59, 1.78) 
Treatment assignment imbalance tolerance level=4 
0.6 4.04 (3.85, 4.23) 3.98 (3.76, 4.19) 4.60 (4.36, 4.84) 
0.7 2.52 (2.40, 2.64) 2.41 (2.28, 2.54) 2.53 (2.40, 2.66) 
0.8 1.97 (1.88, 2.06) 1.70 (1.60, 1.80) 1.77 (1.67, 1.87) 
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Table 4.1.4.3a The comparison of the mean proportion of clinical sites with more than 15 
patients for whom the absolute difference between the numbers of patients in two treatment 
groups at that site is 5 or greater for each dataset over 1,000 simulated treatment allocations 
for one stratification factor with two or three levels when clinical site is included as one of the 
stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
1 factor 
with 2 
levels 
Treatment assignment imbalance tolerance level=2 
0.6 0.159 (0.155, 0.162) 0.153 (0.150, 0.156) 0.216 (0.213, 0.218) 
0.7 0.046 (0.044, 0.049) 0.040 (0.038, 0.041) 0.044 (0.043, 0.045) 
0.8 0.010 (0.009, 0.011) 0.008 (0.008, 0.009) 0.009 (0.008, 0.010) 
Treatment assignment imbalance tolerance level=3 
0.6 0.174 (0.170, 0.178) 0.170 (0.167, 0.173) 0.235 (0.232, 0.237) 
0.7 0.067 (0.065, 0.069) 0.061 (0.059, 0.063) 0.069 (0.068, 0.071) 
0.8 0.023 (0.022, 0.025) 0.021 (0.020, 0.022) 0.021 (0.020, 0.022) 
Treatment assignment imbalance tolerance level=4 
0.6 0.190 (0.186, 0.194) 0.188 (0.185, 0.191) 0.263 (0.260, 0.265) 
0.7 0.094 (0.091, 0.097) 0.086 (0.084, 0.088) 0.101 (0.100, 0.103) 
0.8 0.046 (0.044, 0.049) 0.041 (0.039, 0.042) 0.043 (0.042, 0.045) 
1 factor 
with 3 
levels 
Treatment assignment imbalance tolerance level=2 
0.6 0.155 (0.151, 0.158) 0.153 (0.150, 0.155) 0.214 (0.211, 0.216) 
0.7 0.046 (0.044, 0.048) 0.041 (0.040, 0.043) 0.043 (0.042, 0.045) 
0.8 0.009 (0.008, 0.010) 0.008 (0.008, 0.009) 0.009 (0.008, 0.009) 
Treatment assignment imbalance tolerance level=3 
0.6 0.176 (0.172, 0.179) 0.171 (0.168, 0.174) 0.237 (0.234, 0.239) 
0.7 0.068 (0.065, 0.070) 0.061 (0.059, 0.062) 0.070 (0.069, 0.072) 
0.8 0.024 (0.022, 0.026) 0.020 (0.018, 0.021) 0.022 (0.021, 0.022) 
Treatment assignment imbalance tolerance level=4 
0.6 0.193 (0.190, 0.197) 0.188 (0.185, 0.191) 0.263 (0.260, 0.265) 
0.7 0.094 (0.091, 0.098) 0.087 (0.085, 0.089) 0.101 (0.099, 0.103) 
0.8 0.047 (0.045, 0.050) 0.041 (0.040, 0.043) 0.043 (0.042, 0.044) 
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Table 4.1.4.3b The comparison of the mean proportion of clinical sites with more than 15 
patients for whom the absolute difference between the numbers of patients in two treatment 
groups at that site is 5 or greater for each dataset over 1,000 simulated treatment allocations 
for three stratification factors with varying levels when clinical site is included as one of the 
stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
3 factors 
(1 with 2 
levels and 2 
with 3 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 0.214 (0.210, 0.218) 0.215 (0.212, 0.218) 0.321 (0.318, 0.324) 
0.7 0.085 (0.082, 0.088) 0.079 (0.077, 0.081) 0.095 (0.093, 0.096) 
0.8 0.024 (0.023, 0.026) 0.020 (0.019, 0.021) 0.020 (0.019, 0.021) 
Treatment assignment imbalance tolerance level=3 
0.6 0.223 (0.218, 0.227) 0.223 (0.220, 0.226) 0.333 (0.330, 0.335) 
0.7 0.098 (0.095, 0.101) 0.093 (0.091, 0.095) 0.113 (0.112, 0.115) 
0.8 0.036 (0.035, 0.038) 0.031 (0.030, 0.033) 0.035 (0.034, 0.036) 
Treatment assignment imbalance tolerance level=4 
0.6 0.226 (0.222, 0.230) 0.226 (0.222, 0.229) 0.342 (0.340, 0.345) 
0.7 0.114 (0.111, 0.117) 0.107 (0.105, 0.109) 0.133 (0.131, 0.135) 
0.8 0.054 (0.052, 0.056) 0.047 (0.045, 0.048) 0.050 (0.049, 0.051) 
3 factors 
 (all with 3 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 0.217 (0.212, 0.221) 0.212 (0.209, 0.216) 0.326 (0.323, 0.329) 
0.7 0.085 (0.082, 0.087) 0.079 (0.077, 0.081) 0.094 (0.093, 0.096) 
0.8 0.024 (0.022, 0.025) 0.020 (0.019, 0.021) 0.020 (0.019, 0.021) 
Treatment assignment imbalance tolerance level=3 
0.6 0.218 (0.214, 0.223) 0.220 (0.217, 0.223) 0.331 (0.329, 0.334) 
0.7 0.099 (0.095, 0.102) 0.091 (0.089, 0.094) 0.113 (0.112, 0.115) 
0.8 0.037 (0.035, 0.039) 0.032 (0.031, 0.034) 0.035 (0.034, 0.036) 
Treatment assignment imbalance tolerance level=4 
0.6 0.229 (0.225, 0.233) 0.226 (0.223, 0.229) 0.340 (0.337, 0.343) 
0.7 0.114 (0.110, 0.117) 0.110 (0.107, 0.112) 0.133 (0.131, 0.135) 
0.8 0.051 (0.049, 0.053) 0.046 (0.044, 0.047) 0.052 (0.051, 0.053) 
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Table 4.1.4.4 The comparison of the mean proportion of clinical sites with more than 15 
patients for whom the absolute difference between the numbers of patients in two treatment 
groups at that site is 5 or greater for each dataset over 1,000 simulated treatment allocations 
for different numbers of stratification factors when clinical site is included as one of the 
stratification factors. 
Number of 
stratification 
factors and  
stratification 
factor levels 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
n=1,801 n=3,060 n=13,388 
Mean 95% CI Mean 95% CI Mean 95% CI 
2 factors 
(both are 
with 3 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 0.193 (0.189, 0.197) 0.189 (0.186, 0.192) 0.275 (0.273, 0.278) 
0.7 0.064 (0.061, 0.066) 0.059 (0.057, 0.060) 0.068 (0.066, 0.069) 
0.8 0.015 (0.014, 0.016) 0.013 (0.012, 0.014) 0.013 (0.013, 0.014) 
Treatment assignment imbalance tolerance level=3 
0.6 0.203 (0.199, 0.207) 0.197 (0.193, 0.200) 0.290 (0.287, 0.292) 
0.7 0.082 (0.079, 0.085) 0.075 (0.073, 0.077) 0.090 (0.089, 0.092) 
0.8 0.030 (0.029, 0.032) 0.026 (0.024, 0.027) 0.027 (0.026, 0.028) 
Treatment assignment imbalance tolerance level=4 
0.6 0.208 (0.203, 0.212) 0.210 (0.207, 0.213) 0.304 (0.302, 0.307) 
0.7 0.105 (0.102, 0.108) 0.096 (0.094, 0.098) 0.117 (0.115, 0.119) 
0.8 0.047 (0.045, 0.049) 0.041 (0.039, 0.042) 0.045 (0.044, 0.046) 
4 factors 
 (3 with 3 
levels and 1 
with 2 
levels) 
Treatment assignment imbalance tolerance level=2 
0.6 0.234 (0.230, 0.238) 0.234 (0.230, 0.237) 0.359 (0.356, 0.362) 
0.7 0.104 (0.101, 0.107) 0.099 (0.096, 0.101) 0.123 (0.121, 0.125) 
0.8 0.031 (0.029, 0.033) 0.029 (0.027, 0.030) 0.031 (0.030, 0.032) 
Treatment assignment imbalance tolerance level=3 
0.6 0.238 (0.234, 0.243) 0.238 (0.235, 0.241) 0.365 (0.363, 0.368) 
0.7 0.117 (0.113, 0.120) 0.108 (0.106, 0.111) 0.137 (0.135, 0.139) 
0.8 0.044 (0.042, 0.046) 0.039 (0.037, 0.040) 0.042 (0.041, 0.043) 
Treatment assignment imbalance tolerance level=4 
0.6 0.242 (0.238, 0.247) 0.241 (0.238, 0.244) 0.371 (0.368, 0.373) 
0.7 0.128 (0.124, 0.131) 0.123 (0.121, 0.126) 0.154 (0.152, 0.156) 
0.8 0.060 (0.058, 0.063) 0.052 (0.051, 0.054) 0.059 (0.058, 0.060) 
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4.2 PROBABILITY OF PREDICTING TREATMENT ALLOCATION 
The probability of predicting the next treatment allocation is calculated for each of the three 
NSABP trials using the three predictive methods defined in Section 3.3.2.  Different treatment 
allocation imbalance tolerance levels and different assignment probabilities of the biased-coin in 
the minimization algorithm are considered.   
Table 4.2.1 displays the mean treatment allocation predictability rates based on the 
predictive method 1 in which the prediction based upon knowledge of the previous treatment 
allocation only.  When clinical site is not included as one of the stratification factors, the change 
in mean predictability rates for predictive method 1 is minimal no matter what the treatment 
allocation imbalance tolerance level or the treatment allocation probability is considered and all 
values are 0.508 or less (Table 4.2.1a).  When the clinical site is included as one of the 
stratification factors (Table 4.2.1b), the mean predictability rates for predictability method 1 are 
increased compared to that when site is not included.  However, the maximum value even in the 
extreme situation of 0.8 biased-coin probability is still relatively low at 0.554.  When considering 
more reasonable scenario with treatment imbalance tolerance level of 4 and a biased-coin 
probability of 0.6, the largest predictability rate is only 0.512.  In general, predictability rates 
tends to decrease as the treatment imbalance tolerance level increases from 2 to 4, and it 
increases as the assignment probabilities of the biased-coin increases from 0.6 to 0.8.  Also, from 
comparison of the predictability rates across the three trials, it can be seen that the predictability 
rate decreases only slightly as the sample size of trial becomes larger. 
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Table 4.2.1a The mean treatment allocation predictability rates for each trial based on 
predictive method 1 over 1,000 simulations when clinical site is not included as one of the 
stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.502 (0.501, 0.502) 0.502 (0.502, 0.503)  0.503 (0.5028, 0.5033) 
0.7 0.502 (0.501, 0.503) 0.503 (0.502, 0.503)  0.506 (0.5056, 0.5062) 
0.8 0.504 (0.503, 0.505) 0.503 (0.502, 0.504)  0.508 (0.5076, 0.5082) 
Treatment assignment imbalance tolerance level=3 
0.6 0.502 (0.501, 0.502) 0.502 (0.502, 0.503)  0.503 (0.5028, 0.5034) 
0.7 0.503 (0.502, 0.503) 0.503 (0.502, 0.503)  0.506 (0.5055, 0.5061) 
0.8 0.503 (0.502, 0.504) 0.503 (0.503, 0.504)  0.507 (0.5068, 0.5074) 
Treatment assignment imbalance tolerance level=4 
0.6 0.501 (0.500, 0.502) 0.502 (0.501, 0.502)  0.503 (0.5025, 0.5031) 
0.7 0.502 (0.502, 0.503) 0.502 (0.502, 0.503)  0.505 (0.5050, 0.5056) 
0.8 0.502 (0.501, 0.503) 0.503 (0.503, 0.504)  0.507 (0.5064, 0.5069) 
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Table 4.2.1b The mean treatment allocation predictability rates for each trial based on 
predictive method 1 over 1,000 simulations when clinical site is included as one of the 
stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.517 (0.516, 0.518) 0.510 (0.509, 0.510)  0.507 (0.5065, 0.5071) 
0.7 0.535 (0.534, 0.536) 0.524 (0.523, 0.524)  0.517 (0.5172, 0.5178) 
0.8 0.554 (0.553, 0.555) 0.540 (0.540, 0.541)  0.532 (0.5320, 0.5326) 
Treatment assignment imbalance tolerance level=3 
0.6 0.514 (0.513, 0.515) 0.510 (0.509, 0.510)  0.507 (0.5065, 0.5071) 
0.7 0.528 (0.528, 0.529) 0.522 (0.521, 0.522)  0.516 (0.5160, 0.5166) 
0.8 0.541 (0.540, 0.542) 0.534 (0.533, 0.535)  0.528 (0.5281, 0.5287) 
Treatment assignment imbalance tolerance level=4 
0.6 0.512 (0.511, 0.513) 0.509 (0.508, 0.510)  0.507 (0.5063, 0.5069) 
0.7 0.523 (0.522, 0.524) 0.520 (0.519, 0.521)  0.515 (0.5152, 0.5158) 
0.8 0.532 (0.531, 0.533) 0.529 (0.529, 0.530)  0.525 (0.5249, 0.5255) 
The mean treatment allocation predictability rates based on the predictive method 2 
(based upon knowledge of all previous allocations to the clinical site) and the predictive method 
3 (based upon only the previous three allocations to the clinical site) are summarized in Table 
4.2.2 and Table 4.2.3, respectively.  The patterns seen for predictive methods 2 and 3 are similar 
to those seen for predictive method 1.  The maximum value of the mean treatment allocation 
predictability rates based on predictive methods 2 and 3 in the extreme situation of 0.8 bias-coin 
probability is 0.604 and 0.571, respectively.  Comparing the predictability rates from the three 
different predictive methods, the mean predictability rates are quite close for all three methods 
when clinical site is not included as one of the stratification factors and it was not possible to 
predict the next treatment allocation with any consistency or any real improvement over chance.  
When clinical site is included as a stratification factor, the predictability rates are higher than 
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when clinical site is not included and as expected, more sophisticated methods (method 2 and 
method 3) introduce higher predictability rate than method 1.  However, when dealing with the 
more reasonable situation of a biased-coin probability of 0.6 and treatment imbalance tolerance 
of 4, the predictability rates never exceed 0.526 which would still be a very small gain over a 
pure random guess.  
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Table 4.2.2a The mean predictability rates for each trial based on predictive method 2 
over 1,000 simulations when clinical site is not included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.501 (0.501, 0.502)  0.501 (0.500, 0.502) 0.501 (0.5008, 0.5014) 
0.7 0.501 (0.500, 0.502)  0.501 (0.500, 0.502) 0.501 (0.5009, 0.5015) 
0.8 0.502 (0.501, 0.503)  0.501 (0.501, 0.502) 0.502 (0.5015, 0.5021) 
Treatment assignment imbalance tolerance level=3 
0.6 0.502 (0.501, 0.502)  0.501 (0.501, 0.502) 0.501 (0.5008, 0.5014) 
0.7 0.502 (0.501, 0.503)  0.501 (0.501, 0.502) 0.501 (0.5010, 0.5016) 
0.8 0.502 (0.501, 0.503)  0.501 (0.500, 0.501) 0.501 (0.5011, 0.5017) 
Treatment assignment imbalance tolerance level=4 
0.6 0.501 (0.500, 0.502)  0.501 (0.500, 0.501) 0.501 (0.5004, 0.5010) 
0.7 0.501 (0.500, 0.502)  0.501 (0.500, 0.502) 0.501 (0.5009, 0.5015) 
0.8 0.501 (0.500, 0.502)  0.501 (0.500, 0.502) 0.501 (0.5012, 0.5018) 
Table 4.2.2b The mean predictability rates for each trial based on predictive method 2 
over 1,000 simulations when clinical site is included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.535 (0.534, 0.536) 0.523 (0.523, 0.524) 0.527 (0.5265, 0.5270) 
0.7 0.573 (0.572, 0.573) 0.559 (0.558, 0.559) 0.561 (0.5607, 0.5612) 
0.8 0.604 (0.603, 0.604) 0.593 (0.592, 0.593) 0.592 (0.5923, 0.5927) 
Treatment assignment imbalance tolerance level=3 
0.6 0.530 (0.529, 0.531) 0.523 (0.522, 0.523) 0.526 (0.5261, 0.5266) 
0.7 0.559 (0.558, 0.560) 0.553 (0.553, 0.554) 0.557 (0.5572, 0.5576) 
0.8 0.580 (0.580, 0.581) 0.580 (0.579, 0.581) 0.584 (0.5840, 0.5844) 
Treatment assignment imbalance tolerance level=4 
0.6 0.526 (0.525, 0.527) 0.521 (0.521, 0.522) 0.525 (0.5252, 0.5257) 
0.7 0.548 (0.548, 0.549) 0.548 (0.548, 0.549) 0.554 (0.5536, 0.5541) 
0.8 0.564 (0.563, 0.565) 0.570 (0.569, 0.570) 0.577 (0.5768, 0.5772) 
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Table 4.2.3a The mean predictability rates for each trial based on predictive method 3 
over 1,000 simulations when clinical site is not included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.502 (0.501, 0.502) 0.501 (0.501, 0.502) 0.502 (0.5021, 0.5026) 
0.7 0.502 (0.501, 0.503) 0.502 (0.501, 0.502) 0.504 (0.5039, 0.5045) 
0.8 0.503 (0.502, 0.504) 0.502 (0.502, 0.503) 0.505 (0.5051, 0.5057) 
Treatment assignment imbalance tolerance level=3 
0.6 0.502 (0.501, 0.503) 0.502 (0.501, 0.502) 0.502 (0.5022, 0.5027) 
0.7 0.502 (0.501, 0.503) 0.502 (0.501, 0.502) 0.504 (0.5037, 0.5043) 
0.8 0.502 (0.501, 0.503) 0.502 (0.501, 0.502) 0.505 (0.5045, 0.5051) 
Treatment assignment imbalance tolerance level=4 
0.6 0.501 (0.500, 0.502) 0.501 (0.501, 0.502) 0.502 (0.5020, 0.5026) 
0.7 0.502 (0.501, 0.503) 0.502 (0.501, 0.502) 0.504 (0.5035, 0.5040) 
0.8 0.501 (0.500, 0.502) 0.502 (0.502, 0.503) 0.504 (0.5043, 0.5048) 
Table 4.2.3b The mean predictability rates for each trial based on predictive method 3 
over 1,000 simulations when clinical site is included as one of the stratification factors. 
Bias-Coin 
Probability 
Used for 
Treatment 
Allocation 
B-24 trial (n=1,801) B-28 trial (n=3,060) P-1 trial (n=13,388) 
Mean 95% CI Mean 95% CI Mean 95% CI 
Treatment assignment imbalance tolerance level=2 
0.6 0.522 (0.521, 0.523) 0.513 (0.512, 0.513) 0.508 (0.5082, 0.5088) 
0.7 0.547 (0.546, 0.548) 0.531 (0.531, 0.532) 0.522 (0.5219, 0.5225) 
0.8 0.571 (0.570, 0.572) 0.553 (0.552, 0.554) 0.540 (0.5401, 0.5406) 
Treatment assignment imbalance tolerance level=3 
0.6 0.519 (0.518, 0.520) 0.512 (0.511, 0.513) 0.508 (0.5082, 0.5087) 
0.7 0.538 (0.537, 0.539) 0.528 (0.528, 0.529) 0.520 (0.5202, 0.5207) 
0.8 0.554 (0.553, 0.555) 0.545 (0.544, 0.546) 0.535 (0.5349, 0.5355) 
Treatment assignment imbalance tolerance level=4 
0.6 0.516 (0.515, 0.517) 0.512 (0.511, 0.512) 0.508 (0.5078, 0.5083) 
0.7 0.531 (0.530, 0.532) 0.526 (0.525, 0.526) 0.519 (0.5187, 0.5193) 
0.8 0.542 (0.541, 0.543) 0.539 (0.538, 0.539) 0.531 (0.5309, 0.5315) 
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4.3 COMPARISON OF RESULTS FROM THE LOG-RANK TEST AND THE 
RANDOMIZATION TEST 
4.3.1 The Comparison of Results from the Log-rank Test and the Randomization Test for 
the Simulated Data Sets based on three NSABP Trials 
To evaluate the performances of the log-rank test and the randomization test for trials using 
biased-coin minimization, we first compared the proportions of the 1,000 simulations in which 
we obtain p-value <0.05 from these two statistical tests to determine the degree to which the 
nominal significance level (5%) is maintained by each test.  Subsequently, we assessed the 
agreement on the significance/ non-significance of p-value from two tests.  The results of 
comparing two tests for the simulated data sets based on three NSABP trials are summarized in 
Table 4.3.1. 
Table 4.3.1 The proportions of the 1,000 simulated data sets in which the p-value is <0.05  
and the inconsistent conclusions for hypothesis testing comparing p-values from the log-
rank test and the randomization test out of 1,000 simulations data sets based on B-24, B-28 
and P-1 trials 
1,000 
simulations 
data sets 
Proportion of 
p-values 
<0.05 from 
log-rank test 
Proportion of p-
values <0.05 from 
randomization 
test 
inconsistent conclusions for hypothesis testing 
from two tests 
Number of 
inconsistent 
(LRT, RT)* (Min, Max)** 
B-24 trial 86.60% 86.70% 12 (4, 8) (0.0044, 0.0161) 
B-28 trial 49.30% 49.30% 15 (7, 8) (0.0031, 0.0125) 
P-1 trial 100% 100% 0 - - 
* LRT value is the number of circumstances where the log rank test rejects but the randomization
test does not reject.  RT value is the number of circumstances where the log rank test does not 
reject but the randomization test does reject. 
** Min and Max are the minimum and the maximum of the difference in the inconsistent cases 
65 
The proportions of p-values <0.05 in the 1,000 simulated data sets based on the B-24 trial 
with hazard ratio of 0.8 from the log-rank test and the randomization test are 86.60% and 
86.70%, respectively.  In the 1,000 simulated data sets based on the B-24 trial, 988 of 1,000 have 
the agreement on the significance/ non-significance of the p-values from the two statistical tests.  
Within the 12 inconsistent cases, 4 are the circumstance where the p-value from the log-rank test 
is significant while the p-value from the randomization test is non-significant and 8 have the 
opposite circumstance.  The minimum of the difference and the maximum of the difference in 
the inconsistent cases of the simulations based on B-24 trial are 0.0044 and 0.0125, respectively. 
The proportions of p-values <0.05 in the 1,000 simulated data sets based on the B-28 trial 
with hazard ratio of 0.9 from the two statistical tests are both 49.30%.       Of 1000 simulations 
based on the B-28 trial, the p-values of 985 (98.5%) have consistent decision on the significance/ 
non-significance of the p-values from two tests and within the 15 inconsistent cases, 7 are the 
circumstance where the p-value from the log-rank test is significant while the p-value from the 
randomization test is non-significant and 8 have the opposite circumstance.  The magnitudes of 
the differences between the p-values from two tests in the inconsistent cases are minimal.  The 
minimum and maximum differences for the inconsistent cases from the B-28 simulations are 
0.0044 and 0.0161, respectively. 
All p-values of 1,000 simulated data sets based on P-1 trail with hazard ratio of 0.5 are 
less than 0.05 from two statistical tests. 
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4.3.2 The Influence of Effect Size on the Comparison of Results from the Log-rank Test 
and the Randomization Test 
To investigate the influence of effect size on the comparison of p-values from two tests, we 
conducted simulations using the stratification parameters from each trial considering 4 different 
scenarios of hazard ratios (i.e. 0.5, 0.6, 0.8, and 0.9) under statistical power of 0.8.  The sample 
sizes required for the simulations under different scenarios of hazard ratio are listed in Table 4.3.2.1.  
Table 4.3.2.1 The sample size required for the simulations using stratification parameters 
in B-24, B-28 and P-1 trials under different scenarios of hazard ratio  
Hazard 
Ratio 
Simulations using the 
stratification parameters 
in B-24 trial 
Simulations using the 
stratification 
parameters in B-28 trial 
Simulations using the 
stratification 
parameters in P-1 trial 
0.5 205 171 1,164 
0.6 353 295 1,975 
0.8 1,654 1,392 9,067 
0.9 7,094 5,987 38,474 
Table 4.3.2.2 shows the number of inconsistent conclusions from hypothesis testing using 
the two statistical tests out of 1,000 simulations based on the stratification parameters of three 
trials under the different scenarios of hazard ratios.  The proportions of inconsistent conclusions 
are less than 2% for each scenario.   Additionally, among the situations with inconsistent 
conclusions the differences between the p-values from two tests are very small.     
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Table 4.3.2.2 The number of inconsistent conclusions for hypothesis testing comparing p-
values from the log-rank test and the randomization test out of 1,000 simulations using 
stratification parameters in B-24, B-28 and P-1 trials  
* Total is the total number of circumstances where the p-value for the log rank test is < 0.05 and
the p-value for the randomization test is > 0.05; or p-value for the log rank test is > 0.05 and the 
p-value for the randomization test is < 0.05. LRT value is the number of circumstances where the 
log rank test rejects but the randomization test does not reject.  RT value is the number of 
circumstances where the log rank test does not reject but the randomization test does reject.   
Hazard 
Ratio 
Inconsistent conclusions for hypothesis testing from two tests 
Simulations using the 
stratification parameters 
in B-24 trial 
Simulations using the 
stratification parameters 
in B-28 trial 
Simulations using the 
stratification parameters 
in P-1 trial 
Total (LRT, RT)* Total (LRT, RT)* Total (LRT, RT)* 
0.5 18 (9, 9) 17 (11, 6) 10 (3, 7) 
0.6 21 (9, 12) 16 (7, 9) 13 (5, 8) 
0.8 13 (3, 10) 11 (6, 5) 10 (6, 4) 
0.9 9 (5, 4) 12 (6, 6) 14 (7, 7) 
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5.0 CONCLUSIONS  
From the results of the balancing properties of the bias-coin minimization we see that, compared 
to complete randomization, minimization indeed substantially decrease the treatment imbalance 
in terms of overall treatment imbalance, the treatment imbalance within stratification factors and 
the treatment imbalance within clinical site.  In this study, we conducted a series of simulations 
to evaluate the balancing properties under various scenarios and we observed that:  
(1) the biased-coin probability used in the minimization algorithm has a larger effect on the 
balancing properties than does the treatment imbalance tolerance level used; 
(2) when more stratification factors are included the overall treatment imbalance is decreased 
but the treatment imbalance within clinical site is increased;  
(3) the inclusion of clinical site as a stratification factor increases the treatment imbalance but 
the imbalance is still within the desired tolerance level; and 
(4) generally speaking, study design factors such as the biased-coin probability used, number of 
stratification variables included,  number of categories within the stratification variables, 
treatment assignment imbalance tolerance and the inclusion of clinical site influence the 
actual achievable level of balance only to a small degree, especially for the study with large 
sample size. 
Selection bias resulting from the foreknowledge of treatment assignment incurs concern 
only if the probability of making a correct prediction is sufficiently large to permit selective 
entry of patients into trial.  There is little potential bias if the prediction rate is only marginally 
greater than that obtained by random guesses.  Compared to a probability of 0.5 for completely 
due to chance, the method of minimization does provide the possibility of an enhanced ability to 
predict treatment allocation.  However, the enhancement is minimal.  The results here showed 
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that, in the most extreme scenarios of using minimization (treatment assignment probability of 
0.8 and treatment imbalance tolerance level of two, with clinical site included as a stratification 
factor) , the mean probability of predicting treatment allocation over 1,000 simulations is not 
greater than 0.6.  When using more reason scenarios of minimization (0.6 for the treatment 
assignment probability and treatment imbalance tolerance level of four), the inclusion of clinical 
site as a stratification factor slightly increases the mean probability of predicting treatment 
assignment to a level of about 0.53 from the probability of 0.503 when clinical site is not 
included as a stratification factor.  We also noticed that the magnitude of change of the 
probability to predict treatment allocation associated with the use of bias-coin minimization 
diminishes when the sample size of trial becomes larger. 
It is widely acknowledged in the statistical literature that the subsequent analysis should 
reflect the design of the study.  Accordingly, any randomization method should be associated 
with a test procedure that is valid under the randomization scheme.  However, when 
minimization is used for treatment allocation in randomized clinical trials, a common practice is 
still to perform hypothesis testing using the test procedures associated with complete 
randomization.  It arouses the concern that whether the Type I error of the test would be inflated 
because of using a different randomization scheme.  Some have suggested that the permutation 
test should be used instead when studies that allocate treatment employing minimization or other 
restricted allocation methods because the method by which treatments are allocated to subjects in 
an experimental design is mirrored in the analysis of that design.  The comparison of the results 
from the log-rank test and the randomization test in this study illustrated that the interpretation 
from two statistical tests are similar.  Out of 1,000 simulated data sets, two statistical tests have 
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over 98% agreement on the significance/ non-significance of the p-value and the magnitude of 
the difference between the p-values from tests in the inconsistent cases are minimal.      
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APPENDIX A 
THE CHARACTERISTICS OF PATIENTS BY TREATMENT GROUPS IN THREE 
NSABP TRIALS  
Table A1, A2 and A3 provide the distributions of some key demographic and tumor 
characteristics by treatment groups for each trial. 
Table A1. The Characteristics of Patients in NSABP B-24 Trial 
Characteristics XRT + Placebo XRT + Tamoxifen 
Number of Patients randomized on Study 902 902 
Age (years)* 
    ≤ 49 33.2 33.6 
    50 – 59 30.6 29.5 
    ≥ 60 36.2 36.9 
Race* 
    White 84.9 86.4 
    Black 7.6 6.3 
    Other 5.6 5.9 
    Unknown 2.0 1.3 
Tumor Size (cm)* 
    ≤ 1.0  82.6 85.1 
    1.1 – 2.0 11.6 9.2 
    ≥ 2.1 4.1 4.6 
    Unknown 1.8 1.1 
    Mean ± SD** 0.46 ± 0.75 0.46 ± 0.82 
Note: * values are percent of randomized patients; ** for patients with known tumor size 
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Table A2. The Characteristics of Patients in NSABP B-28 Trial 
Characteristics AC only AC + Taxol 
Number of Patients randomized on Study 1,529 1,531 
Age (years)* 
    ≤ 39 13.5 14.9 
    40 – 49 36.3 36.6 
    50 – 59 31.7 29.8 
    ≥ 60 18.5 18.7 
Race* 
    White 85.6 85.1 
    Black 7.7 8.1 
    Other 6.4 6.4 
    Unknown 0.3 0.4 
Clinical Tumor Size* 
    ≤ 2.0  50.2 46.1 
    2.1 – 4.0 39.6 40.6 
    ≥ 4.1 9.6 12.7 
    Unknown 0.6 0.6 
    Mean ± SD** 2.5 ± 1.8 2.6 ± 1.7 
No. of Postive Nodes* 
    1 – 3 69.8 69.8 
    4 – 9 26.2 25.8 
    10 + 3.9 4.2 
    Unknown 0.1 0.2 
    Mean ± SD** 3.1 ± 2.8 3.3 ± 3.5 
Type of Surgery* 
    Lumpectomy + AD 46.4 46.6 
    Modified Radical 53.6 53.4 
Estrogen Receptor* 
    Negative or Borderline 33.8 34.3 
    Positive 66.3 65.7 
Progesterone Receptor* 
    Negative or Borderline 37.9 39.5 
    Positive 62.1 60.6 
Note: * values are percent of randomized patients; ** for patients with known tumor size 
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Table A3. The Characteristics of Patients in NSABP P-1 Trial 
Characteristics Placebo Tamoxifen 
Number of Patients randomized on Study 6,599 6,576 
Age (years)* 
    35 – 39 2.8 2.4 
    40 – 49 36.5 36.8 
  50 – 59 30.6 30.9 
    60 – 69 24.1 23.9 
    ≥ 70 6.0 6.0 
Race* 
    White 96.4 96.5 
    Other 3.6 3.5 
Hysterectomy* 
    No 63.6 62.3 
    Yes 36.4 37.7 
History of Lobular Carcinoma in Situ* 
    No 93.8 93.7 
    Yes 6.2 6.3 
1st Degree Relatives with Breast Cancer* 
    0 24.2 23.4 
    1 56.5 57.1 
    2 16.5 16.3 
    ≥ 3 2.7 3.2 
History of Atypical Hyperplasia in the Breast* 
    No 90.7 91.2 
    Yes 9.3 8.8 
Five-Year Predicted Breast Cancer Risk* 
    ≤ 2 25.2 24.9 
    2.01 – 3.00 30.8 31.3 
    3.01 – 5.00 27.1 26.1 
   ≥ 5.01 16.9 17.8 
Note: * values are percent of randomized patients 
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APPENDIX B 
SAS PROGRAM FOR THE ASSESSMENT OF THE PERFORMANCE OF THE 
BIASED-COIN MINIMIZATION ALGORITHM 
The following SAS program was used to conduct 1,000 simulations of treatment allocations and 
the prediction of the next treatment allocation for B-24 trail under the scenario of not considering 
the clinical site as one of the stratification factor.  The SAS programs for other trials or other 
scenarios would be modified based on this program. 
SAS program 
proc sql nowarn noprint; 
select distinct 'site' || strip(put(site,8.)) into :sitearray 
separated by ' ' from b24.b24pt order by site; 
select distinct 'count_' || strip(put(site,8.)) into :countarray 
separated by ' ' from b24.b24pt order by site; 
select distinct 'first_trt_' || strip(put(site,8.)) into :firstsitrarray 
separated by ' ' from b24.b24pt order by site; 
select distinct 'sum_trt_' || strip(put(site,8.)) into :sumsitearray 
separated by ' ' from b24.b24pt order by site; 
select distinct 'prev1trt_' || strip(put(site,8.)) into :prev1array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'prev2trt_' || strip(put(site,8.)) into :prev2array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'prev3trt_' || strip(put(site,8.)) into :prev3array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'sum_prev3trt_' || strip(put(site,8.)) into :sum3sitearray 
separated by ' ' from b24.b24pt order by site; 
select distinct 'balance_site' || strip(put(site,8.)) into :balancearray 
separated by ' ' from b24.b24pt order by site; 
select distinct 'preddenom_' || strip(put(site,8.)) into :preddenomarray 
separated by ' ' from b24.b24pt order by site; 
select distinct 'prednum1_' || strip(put(site,8.)) into :prednum1array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'prednum2_' || strip(put(site,8.)) into :prednum2array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'prednum3_' || strip(put(site,8.)) into :prednum3array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'predict1_' || strip(put(site,8.)) into :predict1array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'predict2_' || strip(put(site,8.)) into :predict2array 
separated by ' ' from b24.b24pt order by site; 
select distinct 'predict3_' || strip(put(site,8.)) into :predict3array 
separated by ' ' from b24.b24pt order by site; 
select count(distinct site) into :countsites from b24.b24pt; 
quit; 
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%let iter=1000;  *number of the simulations; 
*imtl: the pre-specified imbalance tolerance level, p: the biased-coin
assignment probability; 
%macro allocation (imtl, p);  
%do rep=1 %to &iter;    
data assign_S&rep; 
  set b24.b24pt end=lastpt; 
  array siteT[&countsites] &sitearray; 
   sitevar = cats('site',site); 
   do i = 1 to dim(siteT); 
       if vname(siteT[i]) = sitevar then siteT[i] = 1; 
       else siteT[i] = 0; 
   end; 
  array first[&countsites] &firstsitrarray; 
  array count[&countsites] &countarray; 
  array sum[&countsites] &sumsitearray; 
  array prev1[&countsites] &prev1array; 
  array prev2[&countsites] &prev2array; 
  array prev3[&countsites] &prev3array; 
  array sum3[&countsites] &sum3sitearray; 
  array balance[&countsites] &balancearray; 
  array preddenom[&countsites] &preddenomarray; 
  array prednum1[&countsites] &prednum1array; 
  array prednum2[&countsites] &prednum2array; 
  array prednum3[&countsites] &prednum3array; 
  array predict1[&countsites] &predict1array; 
  array predict2[&countsites] &predict2array; 
  array predict3[&countsites] &predict3array; 
  /*These variables will be retained from one observation to the next and be 
    initialized with a value of 0.*/ 
  /*Flag variables to denote processing of first observation for a site.*/ 
  retain first (&countsites*0); 
  /*Variables to hold the summed or accumulated count of number of patients 
    for each site.*/ 
  retain count (&countsites*0); 
  /*Variables to hold the summed or accumulated values for trt.*/ 
  retain sum (&countsites*0); 
  /*variable to hold the previous value of trt for each site*/ 
  retain prev1 (&countsites*0); 
  retain prev2 (&countsites*0); 
  retain prev3 (&countsites*0); 
  /*Variables to hold the summed or accumulated values for the most recent 
    previous 3 trt.*/ 
  retain sum3 (&countsites*0); 
  retain balance(&countsites*0) preddenom(&countsites*0) 
         prednum1(&countsites*0) prednum2(&countsites*0)  
         prednum3(&countsites*0) predict1(&countsites*0)  
         predict2(&countsites*0) predict3(&countsites*0); 
  retain first_all balance_all 0; 
  retain imsf1 - imsf2 treatment totimb 0; 
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   /*calculate the total imbalance of previous allocations based on the 
    characteristics of the new patinet to be assigned*/    
   totimb=sf1*imsf1+sf2*imsf2; 
   /*prediction of the treatment allocation fo the new patient*/ 
   do i=1 to dim(siteT); 
     if siteT[i]=1 then do; 
       /*Always increment count for site.*/ 
       count[i] + 1; 
       /*Are we on the first observation for each site?*/ 
       /*If so, first_trt_4 will have a value 0.*/ 
       if first[i] = 0 then do; 
         first[i] = 1; *change value from 0 to 1; 
         guesstrt1 = 2*rantbl(0,0.5,0.5)-3; 
         guesstrt2 = 2*rantbl(0,0.5,0.5)-3;    
         guesstrt3 = 2*rantbl(0,0.5,0.5)-3; 
       end; 
       /*Otherwise, must be on the second or subsequent observation for each 
site.*/ 
       else do; 
 /*prediction method 1- based upon knowledge of the previous treatment 
allocation, whereby the alternative treatment to that previously 
allocated to the center is predicted*/ 
if prev1[i]=1 then guesstrt1= -1; 
else guesstrt1=1; 
/*prediction method 2- based upon knowledge of all previous 
allocations to the center and the treatment group with the least 
number of patients is predicted*/  
if sum[i] > 0 then guesstrt2 = -1; 
else if sum[i] = 0 then guesstrt2 = 2*rantbl(0,0.5,0.5)-3; 
else guesstrt2 = 1;  *sum[i] must have been < 0; 
/*prediction method 3- based upon only the previous 3 allocations 
to the center and the treatment group with the least number of 
patients is predicted*/  
if sum3[i] > 0 then guesstrt3 = -1; 
else if sum3[i] = 0 then guesstrt3 = 2*rantbl(0,0.5,0.5)-3; 
else guesstrt3 = 1;  *sum3[i] must have been < 0; 
        end; 
 /*decide the allocation for the new patient*/ 
*Assign -1 or 1 with probability 0.5 if totimb<=&itl;
       if abs(totimb)<=&imtl then treatment=2*rantbl(0,0.5,0.5)-3; 
*Assign -1 (treatment B) with probability &p and 1 (treatment A) with
        probability 1-&p if number of patients in treatment A > number of  
        patients in treatment B, otherwise assign 1 with probability &p and 
–1 with probability 1-&p;
       else treatment=-sign(totimb)*(2*rantbl(0,1-&p,&p)-3); 
 /*prediction_each site*/ 
 if (prev1[i] ne 0 and sum[i]= 0) then do; balance[i]+1; end; 
 if ((prev1[i] ne 0) and (sum[i] ne 0)) then do; preddenom[i]+1; end; 
       if (((prev1[i] ne 0) and (sum[i] ne 0)) and (guesstrt1=treatment))  
then do; prednum1[i]+1; end; 
       if (((prev1[i] ne 0) and (sum[i] ne 0)) and (guesstrt2=treatment)) 
then do; prednum2[i]+1; end;  
       if (((prev1[i] ne 0) and (sum[i] ne 0)) and (guesstrt3=treatment)) 
then do; prednum3[i]+1; end; 
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 if preddenom[i]=0 then do; 
         predict1[i]=0; 
         predict2[i]=0; 
         predict3[i]=0; 
   end; 
       else do; 
predict1[i]=prednum1[i]/preddenom[i]; 
predict2[i]=prednum2[i]/preddenom[i]; 
predict3[i]=prednum3[i]/preddenom[i]; 
       end; 
 /*overall prediction*/ 
 if prev1[i] = 0 then do; first_all+1; end; 
 if (prev1[i] ne 0 and sum[i]= 0) then do; balance_all+1; end; 
 if ((prev1[i] ne 0) and (sum[i] ne 0)) then do; preddenom_all+1; end; 
       if (((prev1[i] ne 0) and (sum[i] ne 0)) and (guesstrt1=treatment))  
then do; prednum1_all+1; end; 
       if (((prev1[i] ne 0) and (sum[i] ne 0)) and (guesstrt2=treatment)) 
then do; prednum2_all+1; end;  
       if (((prev1[i] ne 0) and (sum[i] ne 0)) and (guesstrt3=treatment)) 
then do; prednum3_all+1; end; 
 if preddenom_all=0 then do; 
predict1_all=0; 
 predict2_all=0; 
 predict3_all=0; 
 end; 
       else do; 
 predict1_all=prednum1_all/preddenom_all; 
 predict2_all=prednum2_all/preddenom_all; 
 predict3_all=prednum3_all/preddenom_all; 
       end; 
 output; *EXPLICIT OUTPUT STATEMENT;
   /*Accumulate the values for trt for each site.*/ 
sum[i] + treatment; 
   /*Accumulate the values for previous 3 trt for site 4.*/ 
*=move the middle to the oldest; 
prev3[i] = prev2[i]; 
*=move the _previous_ most recent to the middle; 
prev2[i] = prev1[i]; 
*assign the current value as the most recent;
prev1[i] = treatment; 
sum3[i]= prev3[i]+prev2[i]+prev1[i]; 
      end; 
    end; 
 /*calculate the imbalance for each level of each stratification factor 
after the new patient is allocated*/  
       imsf1=imsf1+sf1*treatment; 
       imsf2=imsf2+sf2*treatment; 
drop i sitevar; 
run; 
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   proc sql; 
   create table overtrt_S&rep as  
   select sum(treatment=1) as trtA_count, sum(treatment=-1) as trtB_count 
   from assign_S&rep; 
 quit; 
   data sfim_S&rep(keep=imsf1 - imsf2); 
     set assign_S&rep end=lastseq; 
     if lastseq=1; 
   run; 
   proc sql; 
   create table trtbysite_S&rep as  
   select site, sum(treatment=1) as trtA_count, sum(treatment=-1) as  
   trtB_count 
   from assign_S&rep 
   group by site; 
   quit; 
   data siteg15im_S&rep; 
     set trtbysite_S&rep end=last; 
        abs_diff=abs(trtA_count - trtB_count); 
total_count=trtA_count + trtB_count; 
        if ( total_count>15 AND abs_diff>5) then numerator+1; 
 if total_count>15 then denominator+1; 
        if last then siteimg5p=numerator/denominator; 
      if last then output; 
      keep siteimg5p; 
   run; 
   data predict_site_S&rep; 
     set assign_S&rep end=last; 
       if last then output;  
     keep balance_site2 -- balance_site967 preddenom_2 -- preddenom_967 
prednum1_2 -- prednum1_967 prednum2_2 -- prednum2_967 prednum3_2 -- 
prednum3_967 predict1_2 -- predict1_967 predict2_2 -- predict2_967  
predict3_2 -- predict3_967; 
   run; 
   data predict_all_S&rep; 
     set assign_S&rep end=last; 
   if last then output;  
     keep first_all balance_all preddenom_all prednum1_all prednum2_all 
prednum3_all predict1_all predict2_all predict3_all; 
   run; 
%if &rep=1 %then %do; 
  data otrtall; 
    set overtrt_S&rep; 
    iterat=&rep; 
  run; 
  data sfimall; 
    set sfim_S&rep; 
    iterat=&rep; 
  run; 
  data siteimall; 
    set siteg15im_S&rep; 
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iterat=&rep; 
  run; 
  data predict_site_alliter; 
    set predict_site_S&rep; 
iterat=&rep; 
  run; 
  data predict_all_alliter; 
    set predict_all_S&rep; 
iterat=&rep; 
  run; 
%end; 
%else %do; 
  data otrtall; 
    set otrtall overtrt_S&rep(in=latest); 
    if latest then iterat=&rep; 
  run; 
  data sfimall; 
    set sfimall sfim_S&rep(in=latest); 
    if latest then iterat=&rep; 
  run; 
  data siteimall; 
    set siteimall siteg15im_S&rep(in=latest); 
if latest then iterat=&rep; 
  run; 
  data predict_site_alliter; 
    set predict_site_alliter predict_site_S&rep(in=latest); 
iterat=&rep; 
  run; 
  data predict_all_alliter; 
    set predict_all_alliter predict_all_S&rep(in=latest); 
iterat=&rep; 
  run; 
%end;  
%end; 
%mend allocation; 
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APPENDIX C 
SAS PROGRAM FOR THE COMPARISON OF RESULTS FROM THE LOG-RANK 
TEST AND THE RANDOMIZATION TEST 
The following SAS program was used to generate 1,000 simulated datasets based on B-24 trial 
and to execute the stratified log-rank test and the randomization with 1,000 replications for each 
simulated dataset.  The SAS programs for other trials or other scenarios would be modified based 
on this program. 
SAS program 
%let iter=1000; 
%let seed=0; 
%macro gendata;  *Macro of generating the simulated data; 
data genda&iter; 
  AccrualTime=3;  *Accrual time; 
  do ID = 1 to 1801; *Number of patients on study; 
*Generate age_cat based on the distribution of age_cat in B24 population;
    age_cat=rand('TABLE',0.33,0.67)-1;    
*Create two 0/1 incicators for each level of age
       (<50, >=50, respectively);  
if age_cat=0 then sf1=1; else sf1=0; 
if age_cat=1 then sf2=1; else sf2=0; 
*Generate Time from start of accrual to the patient Randomization;
    TimeToRand=rand('uniform')*AccrualTime; 
    output; 
  end; 
drop seed accrualTime; 
run; 
*Sort the simulated data in the order of the randomization sequence;
proc sort data=genda&iter; by TimeToRand; run;  
data trtassign&iter ; 
set genda&iter; 
*Assign treatment group by using the biased-coin minimization;
  /*imsf1 and imsf2 hold the imbalance for each level of age, trt hold the 
    treatment, totimb hold the total imbalance of previous allocations based 
    on the characteristics of the new patient to be assigned  
  /*These variables will be retained from one observation to the next and be 
    initialized with a value of 0 */ 
  retain imsf1 - imsf2 trt totimb 0; 
  /*Calculate the total imbalance of previous allocations based on the 
    characteristics of the new patient to be assigned*/    
  totimb=sf1*imsf1+sf2*imsf2; 
  /*Decide the allocation for the new patient*/ 
*Assign -1 or 1 with probability 0.5 if totimb<=2 (the pre-specified
    imbalance tolerance level); 
  if abs(totimb)<=2 then trt=2*rantbl(0,0.5,0.5)-3; 
*Assign -1 (treatment B) with probability 0.7 and 1 (treatment A) with
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    probability 0.3 if number of patients in treatment A > number of  
    patients in treatment B, otherwise assign 1 with probability p and -1 
    with probability 1-p; 
  else trt=-sign(totimb)*(2*rand('TABLE',1-0.7,0.7)-3); 
  /*Calculate the imbalance for each level of age after the new patient is 
    allocated*/  
  imsf1=imsf1+sf1*trt; 
  imsf2=imsf2+sf2*trt; 
run; 
%mend gendata; 
%macro permtiter;  *Macro of executing logrank test and randomization test;  
%do iter=1 %to &iter; 
%gendata;  *Call the macro of generating the simulated data; 
Data gendata.b24Simdata&iter (keep=id age_cat TimeToRand trt  
TimeToEventTheory TimeOnStudy   
TimeToEventObserved EventCensor); 
  set trtassign&iter; 
  CensorTime=16;  *The whole study time (i.e. the time from the start date of 
accural time to the last date of the follow-up; 
  ControlHazard=0.0374;  *Exponential parameter Lambda for failure rate on 
Control (events per person year); 
   HazardRatio=0.791;  *Ratio of Experimental Hazard Rate to Control Hazard 
Rate; 
  ExperimHazard=ControlHazard*HazardRatio; 
*Generate Time from trial start to Theoretical Event;
  if Trt=1 then 
      TimeToEventTheory=rand('EXPO')/ControlHazard; 
*Generate Time from trial start to Theoretical Event;
  else if Trt=-1 then 
      TimeToEventTheory=rand('EXPO')/ExperimHazard; 
  TimeOnStudy=CensorTime-TimeToRand;  *Time to last follow-up;
  TimeToEventObserved=Min(TimeToEventTheory,TimeOnStudy); 
  if TimeToEventTheory le TimeOnStudy then EventCensor=1;  *Event; 
  else  EventCensor=0;  *Censor; 
Output; 
run; 
   /*Get size of input dataset into macro variable &NUMRECS*/ 
   proc sql noprint; 
    select count(*) into :numrecs from gendata.b24Simdata&iter; 
   quit; 
  /*Generate 1,000 random numbers for each record, so records can be 
    randomly sorted within each replicate*/ 
  data __temp_1_&iter; 
    retain seed 0;  drop seed; 
    set gendata.b24Simdata&iter; 
    do replicate = 1 to 1000;  * ; 
      call ranuni(seed,rand_dep); 
      output; 
    end; 
  run; 
  proc sort data=__temp_1_&iter;  by replicate rand_dep;  run; 
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/* Append the new re-orderings to the original dataset.  
   Label the original as Replicate=0. 
   Then use the ordering of __counter within each replicate to write the   
   original values of &time and &cens, thus creating a randomization of these 
   variables in every replicate.*/ 
  data reps&iter; 
    array timelist{ &NUMRECS } _temporary_ ; 
    array censlist{ &NUMRECS } _temporary_; 
    set gendata.b24Simdata&iter(in=in_orig) __temp_1_&iter(drop=rand_dep); 
    if in_orig then do; 
      replicate=0; 
      timelist{_n_} = TimeToEventObserved ; 
      censlist{_n_} = EventCensor ; 
    end; 
    else do ; 
      TimeToEventObserved = timelist{ 1+mod(_n_,&NUMRECS) }; 
      EventCensor = censlist{ 1+mod(_n_,&NUMRECS) }; 
    end; 
  run; 
proc lifetest data=reps&iter outtest=outI&iter noprint; 
  time TimeToEventObserved*EventCensor(0); 
  strata age_cat/ test=(logrank); 
  test trt;  
  by replicate; 
run; 
data out2I&iter; 
  set outI&iter;  
  if _TYPE_ ='LOG RANK' and _NAME_ = "TimeToEventObserved" then output; 
data out3I&iter; set out2I&iter end = last; retain chisq; 
  if replicate = 0 then chisq = TimeToEventObserved; 
  else do; 
    if TimeToEventObserved + .00000001 ge chisq then num+1; 
  end; 
  if last then do;  
    pvalue = num/(_n_ - 1); 
    stderr = sqrt((pvalue*(1-pvalue))/(_n_ - 1)); 
    lowbound = max(pvalue - 1.96*stderr, 0); 
    upperbound = min(pvalue + 1.96*stderr, 1);  
    n = _n_ - 1; 
    output; 
  end; 
 label n = 'Number of Replicates'; 
  label pvalue = "Randomization Test Estimated P-Value (2-sided)"; 
  label lowbound = 'Lower 95 Pct Bound'; 
  label upperbound = 'Upper 95 Pct Bound'; 
run; 
data logrank_I&iter (drop=replicate); 
  set out2I&iter; 
  if replicate = 0; 
  p = 1 - probchi(TimeToEventObserved, 1); 
  label p = 'Asymptotic P-Value'; 
run; 
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%if &iter=1 %then %do; 
  data testout.permtall; 
set out3I&iter; 
iterat=&iter; 
  run; 
  data testout.logrankall; 
    set logrank_I&iter; 
iterat=&iter; 
  run; 
%end; 
%else %do; 
  data testout.permtall; 
set testout.permtall out3I&iter(in=latest); 
if latest then iterat=&iter; 
  run; 
  data testout.logrankall; 
    set testout.logrankall logrank_I&iter(in=latest); 
if latest then iterat=&iter; 
  run; 
%end;  
%end;  
%mend permtiter; 
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